

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Unintended discontinuation of medication following hospitalisation: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024747
Article Type:	Research
Date Submitted by the Author:	15-Jun-2018
Complete List of Authors:	<p>Redmond, Patrick; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice; THIS Institute (The Healthcare Improvement Studies Institute), University of Cambridge</p> <p>McDowell, Ronald; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research</p> <p>Grimes, Tamasine C.; Trinity Coll Dublin, School of Pharmacy</p> <p>Boland, Fiona; Royal College of Surgeons Ireland, 123 St Stephens Green, HRB Centre For Primary Care Research, Division of Population Health Sciences (PHS)</p> <p>McDonnell, Ronan; Royal College of Surgeons in Ireland, Department of General Practice</p> <p>Hughes, Carmel; Queens University Belfast, School of Pharmacy</p> <p>Fahey, Tom; Royal College of Surgeons in Ireland, Department of General Practice</p>
Keywords:	transitions of care, medication reconciliation, continuity of patient care, cohort study

SCHOLARONE™
Manuscripts

only

1
2
3 **Unintended discontinuation of medication following hospitalisation: a**
4 **retrospective cohort study**
5

6 Patrick Redmond^{1,2}

7 Ronald McDowell²

8 Tamasine Grimes^{2,3}

9 Fiona Boland²

10 Ronan McDonnell²

11 Carmel Hughes^{2,4}

12 Tom Fahey²

13
14
15
16
17
18
19
20
21 ¹ THIS Institute (The Healthcare Improvement Studies Institute), University of
22 Cambridge, United Kingdom.

23
24 ² HRB Centre for Primary Care Research, RCSI medical school, Dublin 2, Ireland

25
26 ³ School of Pharmacy, Trinity College Dublin, Dublin 2, Ireland

27
28 ⁴ School of Pharmacy, Queen's University Belfast, Northern Ireland

29
30
31 **Corresponding author:**

32 Dr Patrick Redmond

33
34 THIS Institute (The Healthcare Improvement Studies Institute)
35 University of Cambridge
36 Cambridge Biomedical Campus, Clifford Allbutt Building,
37 Cambridge CB2 0AH, United Kingdom

38
39 Email: patrick.redmond@thisinstitute.cam.ac.uk

40
41
42
43 **Abstract:** 334 words

44
45 **Main text:** 3,425 words

46
47
48
49 **Keywords:**

50 Transitions of care, medication reconciliation, continuity of patient care, cohort study

Abstract

Objectives: Whether unintended discontinuation of common, evidence based, long-term medication occurs after hospitalisation; what factors are associated with unintended discontinuation; and whether the presence of documentation of medication at hospital discharge is associated with continuity of medication in general practice.

Design: Retrospective cohort study between 2012 and 2015.

Setting: Electronic records and hospital supplied discharge notifications in 44 Irish general practices

Participants: 20,488 patients aged 65 years or more prescribed long-term medication for chronic conditions.

Primary and secondary outcomes: Discontinuity of four evidence-based medication drug classes- antithrombotic, lipid-lowering, thyroid replacement drugs and respiratory inhalers in hospitalised versus non-hospitalised patients; patient and health system factors associated with discontinuity; impact of absence of medication in the hospital discharge summary on continuity of medication in a patient's GP prescribing record at six months follow up.

Results: In patients admitted to hospital, medication discontinuity ranged from 6-11% in the six months post-hospitalisation. Discontinuity of medication is significantly lower for hospitalised patients taking respiratory inhalers (adjusted odds ratio (AOR) 0.63, 95% Confidence Interval (CI) (0.49, 0.80), $p < 0.001$) and thyroid medications (AOR 0.62, 95%CI (0.40, 0.96), $p = 0.03$). There is no association between discontinuity of medication and hospitalisation for antithrombotics (AOR 0.95, 95%CI (0.81, 1.11), $p = 0.49$) or lipid lowering medications (AOR 0.92, 95%CI (0.78, 1.08), $p = 0.29$). Older patients and those who paid to see their GP were more likely to experience increased odds of discontinuity in all four medicine groups. Less than half (39% to 47.4%) of patients had medication listed on their hospital discharge summary. Presence of medication on hospital discharge summary is significantly associated with continuity of medication in the GP prescribing record for lipid lowering medications (AOR 1.64, 95%CI (1.15, 2.36), $p = 0.01$) and respiratory inhalers (AOR 2.97, 95%CI (1.68, 5.25), $p < 0.01$).

1
2
3 **Conclusion:** Discontinuity of evidence-based long-term medication is common.
4 Increasing age and private medical care are independently associated with a higher
5 risk of medication discontinuity. Hospitalisation is not associated with discontinuity
6 but less than half of hospitalised patients have medication recorded on their hospital
7 discharge summary.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Strengths and limitations of this study

1. This study includes prescribing data from a diverse group of general practices that includes non-fee and fee-paying patients.
2. We examined the impact of hospitalisation on continuity of evidence-based, long term medication after discharge.
3. We had no information on reasons for hospitalisation or therapeutic intent in terms of discontinuing medication.
4. We examined a limited number of medication groups and did not report on patient related-outcomes.

Introduction

Older patients are more likely to be prescribed multiple medications, have multiple chronic conditions, and experience increasing number of transitions of care.(1–3) Adherence to clinically appropriate, evidence-based therapies is important for lowering the risk of progression and complications related to their underlying chronic conditions.

Poor coordination of transitions of care is associated with adverse drug events (ADEs), rehospitalisation and discrepancies in medication lists.(4–9) Disruptions in medication continuity following hospitalisation have been reported.(10–13) In particular, omission of medication with known benefit has been noted in prescribing errors at discharge.(14–18) There has been limited assessment of the immediate impact of hospitalisation on medication omission at hospital discharge which in turn, influences general practice repeat prescribing records.(19–23)

Aim and objectives

The aim of this study was to determine whether the potentially unintentional discontinuation of common, evidence-based medications for chronic diseases occurs after hospitalisation among older community dwelling adults. The medicine groups considered are: antithrombotics (antiplatelet or anticoagulants); lipid-lowering medications; thyroid medications; and respiratory inhalers. These medications are commonly prescribed in older populations, have a strong evidence base in terms of efficacy and once started are usually recommended to be continued on a long-term basis. Furthermore, the continuity of these medications in prescribing and dispensing records has been the subject of study internationally – allowing for comparison of results. (11,24–31).

We compare discontinuity of medication for each of the four medicine groups listed above in the GP prescribing record over a six-month period between patients who had been admitted to hospital and a group of patients who had not been admitted to hospital. Second, we examine whether other patient and health-system factors are associated with discontinuity of medication. A third objective is to assess whether

1
2
3 documentation of prescribing of the specific medication in the hospital discharge
4 summary record is associated with the presence of the same medication in the GP's
5 prescribing record in the following six months.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods

Study design

We conducted a retrospective cohort study, adhering to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.⁽³²⁾ Anonymous data were gathered using the general practice patient management system which includes prescribing, demographic and clinical records, and hospital supplied hospitalisation records. Project approval was received from the Irish Primary Care Research Network (IPCRN) and ethical approval was granted from the Irish College of General Practitioners.

Practice recruitment

A data extraction tool was developed with Socrates (providers of Electronic Health Record [EHR] software to a majority of GP practices in Ireland). Following piloting of the extraction tool, a convenience sample of practices using Socrates EHR and receiving electronic hospital discharge communication (n=48) were invited to participate. Forty-four GP practices (response rate 91%) provided consent to take part in the study. Thirty practices were in the catchment area of the Dublin hospitals, with one in the North-East of Ireland. Eleven practices were in the catchment area of the Galway hospitals and two in the catchment area of the Cork hospitals. Participating GPs were awarded continuing professional development points for their participation.

Medication classes

Four distinct patient cohorts were created based on the four medication classes: antithrombotics, lipid-lowering medications, thyroid medications, and respiratory inhalers (Figure 1 – Medication classes). These medications are commonly prescribed in older populations and once commenced, are usually continued on a long-term basis.

Study, enrolment and follow-up period criteria

The study period for each patient ranged from the 1st of January 2012 to the date when the data was extracted from the GP practice; this varied between practices, with the median time being one year and 180 days (Figure 2 – Study enrolment and

1
2
3 follow-up). The study period included a one-year enrolment period, and a six-month
4 follow-up period. The enrolment period for each medication class was the earliest
5 one-year period post 1st January 2012 over which a patient was continuously
6 prescribed medication from that medication class. Continuously prescribed was
7 defined as two prescriptions issued at least five months apart. No hospitalisations
8 were allowed during the enrolment period to avoid misclassifying patients according
9 to exposure. Patients could not be enrolled before 65 years of age and could be
10 enrolled into more than one of the medication groups.
11
12
13
14
15

16
17 The start of the follow-up period, the period of time where discontinuity of medication
18 was estimated, was marked by an index date. For patients who had been
19 hospitalised, this was assigned as the day following discharge from hospital. For
20 those individuals not experiencing hospitalisation, the index date was randomly
21 assigned following the enrolment period. This method of generating a comparison
22 group has been used previously and is in line with assuming the medications are
23 long-term and unlikely to be discontinued.(11)
24
25
26
27
28
29

30 The follow-up period comprised a six-month period following the index date. For
31 patients who were readmitted to hospital during this six-month period, the start of the
32 follow-up period was reset until after the next discharge until a six-month period free
33 from further hospitalisation was established. For all hospitalised patients the 180-day
34 follow-up period was extended to take account of their length of stay of the relevant
35 admission (reflecting the possibility that patients may have supplies of long-term
36 medication at home). A median length of stay for those hospitalised was added to
37 the unexposed group follow-up period.
38
39
40
41
42
43
44

45 Patients who were categorised as deceased/inactive at the extraction date or who
46 had no consultations after each follow-up period were excluded from the analyses.
47 This avoided misclassifying a patient who may, for example, have died in hospital or
48 was discharged to a long-term care facility and were not under the care of their
49 previous general practitioner.
50
51
52
53
54
55
56
57
58
59
60

Explanatory variables of interest

Hospitalisation was the main explanatory variable of interest. The electronic messaging system *Healthlink* provided discharge messages in 41 practices to signal a hospitalisation (inpatient stay, not Emergency Department attendances). Hospitalisation was coded manually by research centre trained coders in four practices by examining the clinical records directly (one practice provided both *Healthlink* electronic discharge information and manually-coded discharge information). We examined whether patient and health-system variables might be associated with absence (primary analysis) or presence (secondary analysis) of medication in the GP prescribing - age, gender, public / private status, number of GP consultations, polypharmacy or multi-morbidity. (33–38) Medication burden was calculated using RxRisk (33–39). All covariates were measured during the enrolment period. For the third objective, we were interested in hospitalised patients only and whether or not absence of specific medication on their hospital discharge summary note was associated with subsequent omission on their repeat general practice prescribing record.

Outcomes

The primary outcome was discontinuity of medication (failure to renew medication) in one of the four, pre-specified medication classes in the general practitioner record over the follow-up period. For each medication class, discontinuity of medication was compared between those who had been hospitalised and those who had not. We calculated univariable associations across the four medication classes and adjusted for important confounders and other explanatory variables of interest. The secondary outcome was presence of relevant medication in the patient's general practice prescribing record following discharge from hospital. Again, this was estimated for each medication cohort.

Sample size

The pilot phase and previous international studies in this area informed the calculation (11,12). Sample size calculation was based on 90% power to detect a 3% difference in the proportion of patients experiencing discontinuity. We assumed 11%

1
2
3 of non-hospitalised patients have medications unintentionally discontinued.
4 Additionally, a 4:1 ratio of non-hospitalised to hospitalised patients (based on
5 experience from the pilot phase) with a statistical significance of 5% was used. This
6 gave a total requirement of 8410 participants in any one medication cohort group.
7
8
9

10 *Plan of analysis*

11 The number of patients at each stage of the study is reported, including those
12 potentially eligible for enrolment, those enrolled into each of the four cohorts, and
13 those available for analysis in the follow-up period. Reasons for removal are
14 documented at each stage.
15
16
17
18
19

20 Descriptive statistics for the primary exposure (hospitalisation) and other explanatory
21 variables are reported. For the primary outcome in each medication class, a
22 multilevel multivariable model was fitted to examine the association between
23 hospitalisation and discontinuity of medication at the follow-up period. Multilevel
24 modelling allows for the fact that patients within any given practice could reasonably
25 be expected to have more in common with each other than with those from a
26 different practice- for instance in terms of prescriber patterns. Models were adjusted
27 for patient and health system variables- age, gender, public/private status, Charlson
28 score (comorbidity), number of repeat drug classes (polypharmacy), and number of
29 enrolment period GP consultations. Results are reported as Adjusted Odds Ratios
30 (AOR) with 95% Confidence Intervals (CI). In addition, we assessed the impact of
31 repeated hospital admissions on discontinuity of medication in the GP prescribing
32 record, using the number of hospital admissions (count variable) between the end of
33 the enrolment period and the beginning of the follow-up period.
34
35
36
37
38
39
40
41
42
43
44

45 For the secondary analyses, multilevel logistic regression was used to examine the
46 association between prescribing of the specified medication at discharge from
47 hospital and presence of the medication in the subsequent GP prescribing history
48 over the next six months. All analyses were performed using Stata V14.(40)
49
50
51
52

53 *Patient and Public Involvement*

54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patients were not involved in the conception, design, or conduct of this research. We plan to disseminate the findings to the public and patients through our contacts in patient representative bodies, the popular media, and through the participating general practices.

For peer review only

Results

Cohort flow

A total of 92,048 patients had their records extracted from the 44 recruited practices, of which 53,921 (58.6%) were removed immediately due to insufficient data (patients with sociodemographic data only, or who had no prescriptions or consultations with the GP after 1 January 2012). (Figure 3 – Participant flow chart) A further 11,871 patients were removed due to not being prescribed any medications from the four drug groups of interest or having less than 12 months of follow-up data available to enable enrolment. The enrolment criteria were applied to the 26,256 remaining patients, creating four cohorts - antithrombotics (Anatomical Therapeutic Chemical (ATC) classification system, B01) (n=13,684), lipid-lowering medications (ATC C10) (n=14,427), thyroid medications (ATC H03) (n=3,484), and respiratory inhalers (ATC R03) (n=5,227). Out of the whole group of patients, 7,896 (38.5%) were enrolled in one medicine group, 9,184 (44.8%) in two groups, 3,074 (15.0%) in three groups and 334 (1.6%) in all four groups.

Descriptive statistics

The demographics of the participants within the four cohorts of those available at the follow-up period are presented in Table 1 (Participant Descriptives). Patients admitted to hospital tended to be slightly older, have more consultations with their general practitioner and higher levels of polypharmacy and co-morbidity during the enrolment period than patients who remained out of hospital.

Among patients who were not hospitalised, the percentage of participants experiencing discontinuation of medication at follow-up ranged from 8.5% (thyroid medications) to 17.0% (respiratory inhalers); and from 5.9% (thyroid medications) to 11.1% (respiratory inhalers) in those who were hospitalised. Levels of discontinuity were higher among those who had not been hospitalised in three of the four drug classes that were examined (Table 1).

Over two thirds of patients did not experience a hospital admission during follow up across the four medication groups (Table 2 – Hospital admissions). Of those admitted to hospital, the percentage of patients experiencing a single admission

1
2
3 ranged between 20.4% and 23.9% across the four medication groups. A minority of
4 patients experienced multiple medical admissions (Table 2).
5

6 7 *Univariable and multivariable associations*

8
9 There is no difference in terms of likelihood of discontinuity for lipid-lowering and
10 antithrombotic drugs between hospitalised and non-hospitalised patients.
11
12 Hospitalisation is associated with less odds of discontinuity of long term medication
13 on those prescribed thyroid medications and respiratory inhalers after adjustment for
14 important confounders (Table 3 – Analysis of Primary outcome). For all four
15 medication groups, older patients are more likely to experience discontinuity of
16 medication than younger patients, with the odds of discontinuity increasing by
17 between 3%-6% per year ($p < 0.001$). Private patients (those who paid for their own
18 prescriptions and their GP visits out of pocket) have the strongest association with
19 discontinuity across all four medicine groups with adjusted odds ratios (AOR) varying
20 between 3.75, (95% CI 2.84, 4.96) for respiratory inhalers to 11.67, (95% CI 8.02,
21 16.96) for thyroid medications (Table 3). Number of consultations, multi-morbidity,
22 number of repeat medications and gender are not associated with an increased odds
23 of discontinuity.
24
25
26
27
28
29
30
31
32

33 *Repeated hospital admissions*

34
35 To assess the impact of repeated hospital admissions, models were re-estimated
36 with the hospital exposure defined as the number of hospital admissions (count)
37 between the end of the enrolment period and the beginning of the follow-up period.
38 For antithrombotics, lipid-lowering medications, and thyroid medications there was
39 no evidence of a statistically significant association between the number of
40 admissions to hospital and discontinuity of medication in the six-month follow up
41 period. However, for respiratory inhalers, the odds of discontinuity of medication fell
42 by an estimated 13% per additional admission to hospital after adjusting for
43 confounders (AOR 0.87, (95%CI 0.76, 0.99), $p = 0.03$). For further details see
44 Supplementary Table 1 (Repeated admissions analysis).
45
46
47
48
49
50
51

52 *Impact of medication specified in patient's hospital discharge summary*

53
54 Recording of medication on the hospital discharge summary was relatively poor, with
55 only 39.2% to 47.4% of patients having the relevant medication group documented
56
57

1
2
3 across the four medication groups. Medication recording had improved at six months
4 post discharge, being present in 89.2% to 94.7% of patient's GP clinical records
5 across medication groups (Table 4 – Documentation of medication at discharge and
6 in the GP record). Having medication listed on hospital discharge summary was
7 independently associated with medication being present on the GP record as six
8 months follow up for both lipid-lowering drugs and respiratory inhalers. Private
9 patients were significantly less likely to have the relevant medication in their GP
10 prescribing record in the six-month period following discharge from hospital than
11 public patients. (Table 5 – Analysis of secondary outcome).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Principal findings

Discontinuation of medication in patients who had been recently hospitalised ranged from 6 to 11% for commonly prescribed, evidence-based medicines, compared to 5-17% for non-hospitalised patients. Patients prescribed thyroid medications and respiratory inhalers, who experienced hospitalisation, actually had a lower risk of discontinuity. Public or private care played a significant role in the likelihood of medication being discontinued with the odds of discontinuation significantly higher for private patients than non-private patients in all medication groups. Increasing age is independently associated with an increased odds of discontinuation of medication. Lastly, recording of medication on hospital discharge summaries is incomplete, being present in less than 50% of discharged patients for all four medication groups. Presence of medication on hospital discharge summaries is associated with continuity on the GP prescribing record at six months for lipid lowering medication and respiratory inhalers.

Previous research

Findings from this observational study differs from similar studies in the US, both in the magnitude of discontinuation: reported to be between 12-19% for thyroid and antithrombotic medications; and in terms of the impact of hospitalisation, with hospitalisation being independently associated with discontinuation, when assessed using pharmacy dispensing data.(8,9,10,41) The impact of hospitalisation appears to be context and health system-specific, with some studies not finding a relationship between discontinuity and hospitalisation.(42–44). We found that increase number of medications was not associated with discontinuation; in the respiratory inhalers group patients were less likely to be discontinued if they had increased numbers of medications.(33,36–38,45–47) Like other studies we found that increasing age was independently associated with an increased discontinuity post discharge.(41)

This study reported a varying discontinuity rate across the four drug classes (lower in antithrombotics and higher in respiratory inhalers). This variation may be explained by disease specific issues: altering doses of thyroxine replacement meaning repeat prescriptions are not required; varying severity of disease – if a patient is

1
2
3 asymptomatic they are less likely to take the medication regularly; evolving
4 diagnoses or clinical considerations to patient beliefs about the effectiveness or
5 benefits of the therapy or their own susceptibility to illness.(48)
6
7

8
9 A particularly interesting finding in our study is the marked difference between
10 publicly funded and privately funded patients. Private patients were found to have a
11 consistent pattern of discontinuity independent of other patient and health system
12 factors (Table 3). Similarly, in hospitalised patients, being a private patient was
13 associated with discontinuity of medication recording in their GP record and
14 significantly more likely at six months follow up. There are possible explanations for
15 this finding. Private patients are not required to have their hospital discharge
16 prescription transcribed by their GP and may proceed directly to the pharmacy,
17 thereby appearing as if their medication has been discontinued by our method of
18 outcome calculation. Nevertheless, lack of continuity in the GP record raises
19 concerns about completeness of the information a GP in relation to a patient's
20 medication file, monitoring requirements, potential drug-to-drug interactions and
21 other potential prescribing errors.
22
23
24
25
26
27
28
29
30

31
32 In keeping with findings from other studies, the quality of prescribing information
33 contained in hospital discharge summaries was incomplete for over half of
34 discharged patients, with the omission of essential medications common.(18,34)
35 Furthermore lack of medication reconciliation upon hospital discharge appeared to
36 persist for at least six months in general practice medication records.(20) The
37 hospital discharge summary used to determine discharge medication in this study is
38 only one element of the information normally provided to patients at discharge from
39 hospital. A supplementary discharge prescription may also be provided.(34)
40 Therefore a discrepancy may arise between the hospital discharge summary and
41 additional discharge prescription, as hospital doctors make judgements about what
42 to include/exclude from discharge prescriptions.(49) These parallel methods of
43 providing post-discharge medication information is a cause for concern and likely
44 enhance risks of medication discontinuity.
45
46
47
48
49
50
51
52
53

54
55 Lastly, whilst lack of medication reconciliation following hospital discharge may be
56 one possible explanation for the reported discontinuity, there are other possible
57
58

1
2
3 explanations, most commonly poor patient adherence. A recent UK study of statin
4 adherence reported discontinuation rates of 27% at one year in those prescribed
5 statins. Notably this was examining primary non-adherence (failure to fill an initial
6 prescription) as distinct from what may be secondary non-adherence (inadequate
7 medication possession over a defined period of time) in this cohort).(50,51) The
8 factors that influence adherence may be patient, therapy, physician or health system
9 related.(52) While this study was able to control for some of these factors
10 (demographics, comorbidities, public/private care status) others were not recorded
11 (socioeconomic status, side-effects, individual physician behaviour and access to
12 healthcare).

22 *Strengths and limitations of study*

23
24 This is the largest Irish study to date to examine the effect of hospitalisation on the
25 continuity of evidence-based medication in the GP prescribing record. It is also the
26 first study to systematically use GP prescribing records (as opposed to pharmacy
27 dispensing records) and includes details of both private and public patients, unique
28 features of the mixed public/private health system in Ireland. The recruitment of GP
29 practices was not limited to one geographically area/hospital catchment and the
30 inclusion of multiple hospitals allowed comparison of messaging standards and their
31 impact on prescribing continuity, enhancing the generalisability of the findings.

32
33
34 There are several limitations to this study. The medication groups were specifically
35 chosen to be evidence-based and long-term in their usage and the establishment of
36 an enrolment period of continuous usage over one year further ensures the pattern
37 of ongoing use. However, the primary outcome of discontinuation of medication was
38 applied to a prescribing database and does not contain information about indication
39 or therapeutic intent, for example intentional discontinuation of statins in end-of-life
40 patients.

41
42
43 The nature of data collection and the dataset itself also incur limitations. Hand written
44 prescriptions were not captured by this data collection technique. The follow-up of
45 participants from enrolment through to outcome calculation also required
46
47
48
49
50
51

1
2
3 assumptions to be made in preparing the data for analysis. However, the methods
4 have been used previously, and are in line with the underlying assumption that there
5 should be no difference between groups with both having 100% persistence of the
6 medication in the GP record. Lastly, the recording of hospitalisation is likely to be
7 variable within practices, with the *Healthlink* service employed differently by hospitals
8 with the possibility of misclassification of exposed individuals. These methodological
9 and data issues were explored in the sensitivity analysis with no change in the
10 overall findings.
11
12
13
14
15

16 17 18 *Clinical and healthcare policy implications*

19
20 The quality of electronic discharge communication received by general practices and
21 the possible association with inappropriate discontinuation of evidence-based
22 medication suggests more emphasis needs to be placed on improving the quality of
23 discharge communication. The HSE's ePrescribing initiative and eScript pilot
24 projects are efforts to improve the transfer of medication information.(53,54)
25
26
27
28
29

30 Future efforts should focus on identifying high-risk individuals who are receiving
31 medications that would be the best targets for reconciliation studies and
32 interventions. Recent efforts have been made to develop a consensus about high
33 risk medications and methods of assessing the potential severity of medication
34 omission.(55)
35
36
37
38
39

40 41 *Conclusions*

42
43 Discontinuity of evidence-based long-term medication is common. Increasing age
44 and private medical care are independently associated with a higher risk of
45 medication discontinuity. Hospitalisation was not associated with discontinuity but
46 less than half of hospitalised patients had medication recorded on their hospital
47 discharge summary. System based solutions that include ePrescribing are needed to
48 enhance the transfer of medication information across the primary/secondary care
49 interface.
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements:

We would like to thank Kevin O'Flannagan, Paul Dillon, Atieh Zarabzadeh, Khalid Munir, Oludare Alabi and Ronan McDonnell for their help in cleaning and categorising prescribing data. *Healthlink*, IPCRN and Socrates in design and data collection. We would also like to acknowledge the GP practices who participated in this study.

Funding:

This study was funded by the Health Research Board of Ireland, HRC-2014-1. This work was conducted as part of the HRB Scholar Programme in Health Services Research under Grant No. PHD/2007/16.

Ethics:

Ethical approval was granted from the Irish College of General Practitioners' Research Ethics Committee. GPs as individual practice data controllers gave informed consent to participate.

Conflict of interests:

We have read and understood BMJ policy on declaration of interests and declare that we have no competing interests.

Author Contributions:

PR initiated the project, designed data collection tools, monitored data collection, wrote the statistical analysis plan, cleaned and analysed the data, and drafted and revised the paper.

RMcDowell wrote the statistical analysis plan, cleaned and analysed the data and revised the paper.

TG designed the data collection tools, wrote the statistical analysis plan, and revised the paper.

FB designed the data collection tools, wrote the statistical analysis plan, and revised the paper.

RMcDonnell designed the data collection tools and revised the paper.

CH initiated the project, advised on the statistical analysis plan, and revised the paper.

1
2
3 TF initiated the project, monitored data collection, advised on the analysis plan and
4 revised the paper. He is guarantor.
5
6

7
8 Data statement

9 *Will individual participant data be available (including data dictionaries)?*
10

11
12 No additional data is available. A data sharing provision was not included in the
13 application to the research ethics committee for approval of this study.
14
15

16
17 *What data in particular will be shared?*
18

19 N/A

20 *What other documents will be available?*
21

22 N/A

23 *When will data be available (start and end dates)?*
24

25 N/A

26 *With whom?*
27

28 N/A

29 *For what types of analyses?*
30

31 N/A

32 *By what mechanism will data be made available?*
33

34 N/A
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012 Jul 7;380(9836):37–43.
2. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. *BMJ Open*. 2015 Sep 18;5(9):e008656.
3. Coleman EA, Smith JD, Raha D, Min SJ. Posthospital medication discrepancies: prevalence and contributing factors. *Arch Intern Med*. 2005 Sep 12;165(16):1842–7.
4. Moore C, Wisnivesky J, Williams S, McGinn T. Medical errors related to discontinuity of care from an inpatient to an outpatient setting. *J Gen Intern Med*. 2003 Aug;18:646–51.
5. van der Linden CMJ, Kerskes MCH, Bijl AMH, Maas HAAM, Egberts ACG, Jansen PAF. Represcription after adverse drug reaction in the elderly: a descriptive study. *Arch Intern Med*. 166(15):1666–7.
6. Coleman E. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. *J Am Geriatr Soc*. 2003 Apr;51(4):549–55.
7. Hammad EA, Wright DJ, Walton C, Nunney I, Bhattacharya D. Adherence to UK national guidance for discharge information: an audit in primary care. *Br J Clin Pharmacol*. 2014 Dec;78(6):1453–64.
8. Boockvar KS, Liu S, Goldstein N, Nebeker J, Siu A, Fried T. Prescribing discrepancies likely to cause adverse drug events after patient transfer. *Qual Saf Health Care*. 2009 Feb;18(1):32–6.
9. Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T. Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. *Arch Intern Med*. 2004 Mar 8;164(5):545–50.
10. Grimmsmann T, Schwabe U, Himmel W. The influence of hospitalisation on drug prescription in primary care--a large-scale follow-up study. *Eur J Clin Pharmacol*. 2007 Aug;63(8):783–90.
11. Bell CM, Brener SS, Gunraj N, Huo C, Bierman AS, Scales DC, et al. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. *JAMA*. 2011 Aug 24;306(8):840–7.
12. Stall NM, Fischer HD, Wu CF, Bierman AS, Brener S, Bronskill S, et al. Unintentional Discontinuation of Chronic Medications for Seniors in Nursing Homes: Evaluation of a National Medication Reconciliation Accreditation Requirement Using a Population-Based Cohort Study. *Medicine (Baltimore)*. 2015 Jun;94(25):e899.
13. Bell CM, Bajcar J, Bierman AS, Li P, Mamdani MM, Urbach DR. Potentially

- unintended discontinuation of long-term medication use after elective surgical procedures. *Arch Intern Med*. 2006 Dec 11;166(22):2525–31.
14. Latimer SL, Chaboyer W, Hall T. Non-Therapeutic Medication Omissions: Incidence and Predictors at an Australian Hospital. *J Pharm Pract Res*. 2011 Sep;41(3):188–91.
 15. Perren A, Previsdomini M, Cerutti B, Soldini D, Donghi D, Marone C. Omitted and unjustified medications in the discharge summary. *Qual Saf Health Care*. 2009 Jun;18(3):205–8.
 16. Belda-Rustarazo S, Cantero-Hinojosa J, Salmeron-García a, González-García L, Cabeza-Barrera J, Galvez J. Medication reconciliation at admission and discharge: an analysis of prevalence and associated risk factors. *Int J Clin Pract*. 2015 Jul 22;1–7.
 17. Elliott RA, Tran T, Taylor SE, Harvey PA, Belfrage MK, Jennings RJ, et al. Gaps in continuity of medication management during the transition from hospital to residential care: an observational study (MedGap Study). *Australas J Ageing*. 2012 Dec;31(4):247–54.
 18. Wong JD, Bajcar JM, Wong GG, Alibhai SMH, Huh J-H, Cesta A, et al. Medication reconciliation at hospital discharge: evaluating discrepancies. *Ann Pharmacother*. 2008 Oct;42(10):1373–9.
 19. Cochrane RA, Mandal AR, Ledger-Scott M, Walker R. Changes in drug treatment after discharge from hospital in geriatric patients. *BMJ*. 1992 Sep 19;305(6855):694–6.
 20. O’Riordan C, Grimes T. Medication reconciliation on discharge to primary care following an acute hospital admission. *Int J Clin Pharm*. 2014;36(4):836.
 21. Mansur N, Weiss A, Hoffman A, Gruenewald T, Beloosesky Y. Continuity and adherence to long-term drug treatment by geriatric patients after hospital discharge: a prospective cohort study. *Drugs Aging*. 2008;25(10):861–70.
 22. Viktil KK, Blix HS, Eek AK, Davies MN, Moger TA, Reikvam A. How are drug regimen changes during hospitalisation handled after discharge: a cohort study. *BMJ Open*. 2012 Nov 19;2(6):e001461–e001461.
 23. Hammad E, Cadman B, Bale A, Holland R, Nunney I, Barton G, et al. Medication errors: Do they persist in primary care and can they be identified? In: Royal Pharmaceutical Society (RPS) Annual Conference. Birmingham, UK;
 24. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. *JAMA*. 1998 May 13;279(18):1458–62.
 25. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *JAMA*. 288(4):455–61.
 26. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions. *Pharmacotherapy*. 2008 Apr;28(4):437–43.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
27. Ganz DA, Glynn RJ, Mogun H, Knight EL, Bohn RL, Avorn J. Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism. *J Gen Intern Med*. 2000 Nov;15(11):776–81.
28. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. *Ann Intern Med*. 2003 May 20;138(10):831–8.
29. Izquierdo JL, Paredero JM, Piedra R. Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. *Int J Chron Obstruct Pulmon Dis*. 2016;11:289–93.
30. National Clinical Guideline Centre(UK). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Institute for Health and Clinical Excellence: Guidance. 2014.
31. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. *Can Respir J*. 10 Suppl A:11A–65A.
32. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007 Oct 16;147(7624):806–8.
33. Hu SH, Capezuti E, Foust JB, Boltz MP, Kim H. Medication discrepancy and potentially inappropriate medication in older Chinese-American home-care patients after hospital discharge. *Am J Geriatr Pharmacother*. 2012 Oct;10(5):284–95.
34. Grimes TC, Duggan C, Delaney TP, Graham IM, Conlon KC, Deasy E, et al. Medication details documented on hospital discharge: cross-sectional observational study of factors associated with medication non-reconciliation. *Br J Clin Pharmacol*. 2011 Mar;71(3):449–57.
35. Feldman LS, Costa LL, Feroli ER, Nelson T, Poe SS, Frick KD, et al. Nurse-pharmacist collaboration on medication reconciliation prevents potential harm. *J Hosp Med*. 2012 May;7(5):396–401.
36. Cornu P, Steurbaut S, Leysen T, De Baere E, Ligneel C, Mets T, et al. Discrepancies in medication information for the primary care physician and the geriatric patient at discharge. *Ann Pharmacother*. 2012 Jul;46(7–8):983–90.
37. Stitt DM, Elliott DP, Thompson SN. Medication discrepancies identified at time of hospital discharge in a geriatric population. *Am J Geriatr Pharmacother*. 2011 Aug;9(4):234–40.
38. Hellström LM, Bondesson Å, Höglund P, Eriksson T. Errors in medication history at hospital admission: prevalence and predicting factors. *BMC Clin Pharmacol*. 2012;12:9.
39. Sloan KL, Sales AE, Liu C-F, Fishman P, Nichol P, Suzuki NT, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. *Med Care*. 2003 Jun;41(6):761–74.

- 1
- 2
- 3 40. StataCorp. Stata Statistical Software. College Station, TX;
- 4
- 5 41. Stuffken R, Heerdink ER, de Koning FHP, Souverein PC, Egberts ACG.
6 Association between hospitalization and discontinuity of medication therapy
7 used in the community setting in the Netherlands. *Ann Pharmacother*. 2008
8 Jul;42(7):933–9.
- 9
- 10 42. Nelson LA, Graham M, Schaefer M. Characterization of Medication
11 Discrepancies Occurring at the Time of Discharge From an Adult State
12 Psychiatric Inpatient Facility. *Hosp Pharm*. 2011 Apr;46(4):254–61.
- 13
- 14 43. Cornish PL, Knowles SR, Marchesano R, Tam V, Shadowitz S, Juurlink DN, et
15 al. Unintended medication discrepancies at the time of hospital admission.
16 *Arch Intern Med*. 2005 Feb 28;165(4):424–9.
- 17
- 18 44. Climente-Martí M, García-Mañón ER, Artero-Mora A, Jiménez-Torres NV.
19 Potential risk of medication discrepancies and reconciliation errors at
20 admission and discharge from an inpatient medical service. *Ann*
21 *Pharmacother*. 2010 Nov;44(11):1747–54.
- 22
- 23 45. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug
24 events occurring following hospital discharge. *J Gen Intern Med*. 2005
25 Apr;20(4):317–23.
- 26
- 27 46. Grimes TC, Deasy E, Allen A, O’Byrne J, Delaney T, Barragry J, et al.
28 Collaborative pharmaceutical care in an Irish hospital: uncontrolled before-after
29 study. *BMJ Qual Saf*. 2014 Jul 6;23(7):574–83.
- 30
- 31 47. Dedhia P, Kravet S, Bulger J, Hinson T, Sridharan A, Kolodner K, et al. A
32 quality improvement intervention to facilitate the transition of older adults from
33 three hospitals back to their homes. *J Am Geriatr Soc*. 2009 Sep;57(9):1540–
34 6.
- 35
- 36 48. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic
37 compliance: A review from the patient’s perspective. *Ther Clin Risk Manag*.
38 2008 Feb;4(1):269–86.
- 39
- 40 49. Tully M, Cantrill J. What Hospital Doctors Think GPs Need In A Discharge
41 Summary. In: WONCA Conference (London, UK). London; 2002.
- 42
- 43 50. Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and
44 restarting in patients on statin treatment: prospective open cohort study using
45 a primary care database. *BMJ*. 2016;353(i3305).
- 46
- 47 51. Raebel MA, Schmittiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing
48 Terminology and Definitions of Medication Adherence and Persistence in
49 Research Employing Electronic Databases. *Med Care*. 2013 Aug;51:S11–21.
- 50
- 51 52. Mauskop A, Borden WB. Predictors of statin adherence. *Curr Cardiol Rep*.
52 2011 Dec;13(6):553–8.
- 53
- 54 53. Health Service Executive (HSE). eHealth strategy for Ireland [Internet]. 2013
55 [cited 2016 Jun 7]. Available from: <http://www.ehealthireland.ie/Knowledge-Information-Plan/eHealth-Strategy-for-Ireland.pdf>
- 56
- 57 54. Health Information & Quality Authority (HIQA). National Standard for Patient
- 58
- 59
- 60

1
2
3 Discharge Summary Information. 2013.

- 4 55. Doerper S, Godet J, Alexandra JF, Allenet B, Andres E, Bedouch P, et al.
5 Development and multi-centre evaluation of a method for assessing the
6 severity of potential harm of medication reconciliation errors at hospital
7 admission in elderly. *Eur J Intern Med*. 2015 Sep 21;26(7):491–7.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1

Descriptive statistics for participants in four evidence-based drug classes (ATC code)

Medication Group (No patients enrolled)	Antithrombotics (B01) (n=13,684)		Lipid-lowering (C10) (n=14,427)		Thyroid meds (H03) (n=3,484)		Respiratory inhalers (R03) (n=5,227)	
No. patients at end of follow-up period	Hospitalised (n=2,707)	Non-hospitalised (n=6,152)	Hospitalised (n=2,622)	Non-hospitalised (n=6,944)	Hospitalised (n=586)	Non-hospitalised (n=1,641)	Hospitalised (n=1,067)	Non-hospitalised (n=2,110)
	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)
Age (years)	78.38 (7.06)	75.32 (6.95)	77.05 (6.77)	73.78 (6.45)	78.34 (7.25)	74.59 (7.18)	76.88 (7.02)	74.29(6.90)
No of consultations in enrolment period	18.28 (10.40)	14.80 (9.66)	17.50 (10.09)	13.71 (8.79)	18.76 (10.29)	14.81 (9.10)	19.64 (11.09)	16.07 (10.57)
No of repeat drug classes during enrolment period	8.04 (3.72)	7.01 (3.45)	7.77 (3.75)	6.44 (3.41)	8.59 (4.30)	6.67 (3.87)	9.26 (4.24)	7.99 (4.13)
RxRisk during enrolment period	5.07 (2.05)	4.55 (1.89)	4.99 (2.09)	4.26 (1.97)	5.37 (2.42)	4.36 (2.09)	4.79 (2.18)	4.29 (2.12)
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Female	1,414 (52.23%)	3,176 (51.63%)	1,423 (54.27%)	3,957 (56.98%)	468 (79.86%)	1,349 (82.21%)	626 (58.67%)	1,276 (60.47%)
Insurance type: GMS/DVC	2,495 (92.17%)	5,495 (89.32%)	2,429 (92.64%)	6,194 (89.20%)	537 (91.64%)	1,445 (88.06%)	998 (93.53%)	1,898 (89.95%)
Charlson index of 1 or more	1,400 (51.72%)	2,638 (42.88%)	1,357 (51.75%)	2,736 (39.40%)	290 (49.49%)	543 (33.09%)	690 (64.67%)	1,120 (53.08%)
Patients experiencing one hospitalisation only during first follow-up period	2,011 (74.29%)	-	1,958 (74.68%)	-	457 (77.99%)	-	761 (71.32%)	-
No. (%) patients discontinued during 1 st follow-up period	288 (10.64%)	693 (11.26%)	282 (10.76%)	727 (10.47%)	35 (5.97%)	139 (8.47%)	118 (11.06%)	359 (17.01%)

ATC: Anatomical Therapeutic Chemical classification system

GMS: General Medical Services

DVC: Doctor Visit Card

SD: standard deviation

Table 2

Number of hospital admissions following enrolment for patients assessed for medication discontinuity at follow-up

Medication Group (No patients enrolled)	Antithrombotics (B01) (n=13,684)	Lipid-lowering (C10) (n=14,427)	Thyroid meds (H03) (n=3,484)	Respiratory inhalers (R03) (n=5,227)
No. patients at end of follow-up period				
0	6,152 (69.44%)	6,944 (72.59%)	1,641 (73.69%)	2,110 (66.41%)
1	2,011 (22.70%)	1,958 (20.45%)	457 (20.52%)	761 (23.95%)
2	448 (5.06%)	419 (4.38%)	90 (4.04%)	200 (6.30%)
3	140 (1.58%)	139 (1.45%)	26 (1.17%)	60 (1.89%)
4	25 (0.28%)	50 (5.23%)	5 (0.23%)	27 (0.85%)
5	8 (0.09%)	24 (0.25%)	6 (0.27%)	5 (0.16%)
6	7 (0.08%)	8 (0.09%)	1 (0.04%)	5 (0.16%)
>6	23 (0.26%)	24 (0.25%)	1 (0.04%)	14 (0.44%)

Table 3

Univariable and multivariable associations in four evidence-based drug classes (ATC code)

	Antithrombotics (B01)		Lipid-lowering (C10)		Thyroid meds(H03)		Respiratory inhalers (R03)	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Hospitalised v non-hospitalised	0.95 (0.82,1.10), p=0.49	0.95 (0.81,1.11), p=0.49	1.04 (0.89,1.20), p=0.64	0.92 (0.78,1.08), p=0.29	0.68 (0.46,1.00), p=0.05	0.62 (0.40,0.96), p=0.03	0.62 (0.49,0.78), p=0.001	0.63 (0.49,0.80), p<0.001
Age (years)	1.02 (1.01,1.03), p<0.001	1.03 (1.02,1.04), p<0.001	1.04 (1.03,1.05), p<0.001	1.05 (1.04,1.06), p<0.001	1.03 (1.01,1.05), p=0.002	1.06 (1.04,1.09), p<0.001	1.02 (1.01,1.03), p=0.004	1.04 (1.02,1.05), p<0.001
<u>Gender:</u> Female v Male	1.02 (0.89,1.17), p=0.79	1.00 (0.87,1.15), p=0.99	0.85 (0.74,0.96), p=0.01	0.82 (0.72,0.95), p=0.01	0.84 (0.57,1.24), p=0.38	0.85 (0.56,1.30), p=0.46	1.04 (0.85,1.28), p=0.68	1.03 (0.83,1.27), p=0.79
<u>Insurance type:</u> Private v GMS/DVC patients	5.10 (4.31,6.04), p<0.001	5.35 (4.50,6.34), p<0.001	4.78 (4.06,5.62), p<0.001	5.68 (4.48,6.73), p<0.001	9.79 (6.90,13.89), p<0.001	11.67 (8.02,16.96), p<0.001	3.66 (2.78,4.82), p<0.001	3.75 (2.84,4.96), p<0.001
Number of repeat drug classes	0.99 (0.98,1.01), p=0.56	0.99 (0.97,1.01), p=0.28	1.01 (1.00,1.04), p=0.04	1.01 (0.99,1.04), p=0.24	0.98 (0.95,1.02), p=0.41	0.98 (0.94,1.03), p=0.44	0.97 (0.94,0.99), p=0.01	0.97 (0.94,0.99), p=0.02
<u>Charlson score</u> (>=1 v0)	0.93 (0.80,1.07), p=0.31	0.94 (0.80,1.09), p=0.41	1.05 (0.91,1.21), p=0.48	0.98 (0.84,1.14), p=0.78	0.78 (0.56,1.08), p=0.15	0.80 (0.54,1.15), p=0.22	0.66 (0.53,0.81), p<0.001	0.71 (0.58,0.88), p=0.002
No of consultations in enrolment period	1.00 (0.99,1.01), p=0.62	1.00 (0.99,1.01), p=0.63	1.00 (0.99,1.01), p=0.69	1.00 (0.99,1.01), p=0.75	0.99 (0.97,1.00), p=0.11	1.00 (0.98,1.02), p=0.83	0.99 (0.98,1.00), p=0.02	1.00 (0.99,1.01), p=0.72

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

Table 4

Cross tabulation of patients by presence of medication on hospital discharge summary and in the GP prescribing record at six months following hospitalisation

Medication Group		GP Record		GP record		GP record		GP record	
		Antithrombotics (B01) (n=1,991)†		Lipid-lowering (C10) (n=1,954) †		Thyroid meds(H03) (n=456) †		Respiratory inhalers (R03) (n=757) †	
		Absent	Present	Absent	Present	Absent	Present	Absent	Present
Hospital discharge	Absent	113 (10.55%)	958 (89.45%)	123 (10.35%)	1,065 (89.65%)	16 (6.67%)	224 (93.33%)	65 (14.19%)	393 (85.81%)
Hospital discharge	Present	78 (8.48%)	842 (91.52%)	63 (8.22%)	703 (91.78%)	8 (3.70%)	208 (96.30%)	17 (5.69%)	282 (94.31%)

†patients with medication discontinued at hospital discharge excluded

Table 5

Multivariable association of required medication appearing in GP clinical record following discharge from hospital

	Antithrombotics (B01) (N=1,991)*		Lipid-lowering (C10) (N=1,954)*		Thyroid meds(H03) (N=456)*		Respiratory inhalers (R03) (N=757)*	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Medication listed on discharge summary	1.29 (0.95,1.76), p=0.11	1.34 (0.97,1.87), p=0.08	1.40 (0.99,1.97), p=0.06	1.64 (1.15,2.36), p=0.01	1.86 (0.77,4.43), p=0.16	1.76 (0.70,4.42), p=0.23	2.74 (1.57,4.78), p<0.001	2.97 (1.68,5.25), p<0.001
Age (years)	0.98 (0.96,1.00), p=0.03	0.98 (0.96,1.00), p=0.08	0.96 (0.94,0.98), p<0.001	0.95 (0.93,0.98), p<0.001	0.96 (0.91,1.02), p=0.16	0.96 (0.91,1.02), p=0.16	0.97 (0.94,1.01), p=0.12	0.96 (0.93,1.00), p=0.03
Female v Male	1.02 (0.76,1.38), p=0.90	0.97 (0.70,1.33), p=0.84	1.14 (0.84,1.56), p=0.39	1.15 (0.83,1.59), p=0.41	1.34 (0.52,3.49), p=0.54	1.35 (0.49,3.73), p=0.57	0.93 (0.58,1.50), p=0.77	0.87 (0.53,1.43), p=0.59
Insurance type: Private v GMS/DVC patients	0.18 (0.13,0.26), p<0.001	0.18 (0.12, 0.27), p<0.001	0.19 (0.12,0.28), p<0.001	0.17 (0.11,0.27), p<0.001	0.10 (0.04,0.26), p<0.001	0.10 (0.04,0.26), p<0.001	0.26 (0.14,0.50), p<0.001	0.26 (0.13,0.49), p<0.001
Number of repeat drug classes	1.04 (1.00,1.09), p=0.06	1.04 (0.99,1.09), p=0.11	0.99 (0.94,1.03), p=0.49	1.00 (0.96,1.06), p=0.86	1.06 (0.95,1.18), p=0.30	1.10 (0.96,1.26), p=0.18	1.07 (10.01,1.13), p=0.03	1.08 (1.00,1.15), p=0.06
Charlson score (>=1 v0)	1.14 (0.84,1.54), p=0.40	1.08 (0.79,1.49), p=0.63	0.76 (0.55,1.04), p=0.09	0.79 (0.56,1.11), p=0.18	1.06 (0.46,2.40), p=0.90	0.82 (0.33,2.03), p=0.67	0.98 (0.61,1.58), p=0.94	0.86 (0.52, 1.45), p=0.55
No of consultations in enrolment period	1.01 (0.99,1.03), p=0.19	1.00 (0.99,1.02), p=0.74	0.99 (0.97,1.01), p=0.22	0.99 (0.97,1.01), p=0.16	1.01 (0.97,1.06), p=0.63	0.99 (0.94, 1.04), p=0.63	1.02 (1.00,1.05), p=0.07	1.02 (0.98,1.04), p=0.41

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

World Health Organization Anatomical Therapeutic Chemical (WHO - ATC) Classification System Code*	Drug class/name	Examples
C10	Lipid modifying agents	Statins, ezetimibe etc.
B01 (includes N02BA01)	Antithrombotics (antiplatelet or anticoagulant agents)	Aspirin, clopidogrel, warfarin, novel oral anticoagulants (NOACs) etc.
H03	Thyroid medication	Levothyroxine, carbimazole etc.
R03	Respiratory inhalers	Inhaled anticholinergics, short & long acting beta agonists, inhaled steroids

*ATC code groupings (as above) were used to ensure all component drugs within a class were included (e.g. prasugrel, ticagrelor etc.)
 This chapter refers to each cohort by the first three figures of the ATC group.

Figure 1 Medication classes

Figure 1 Medication classes
 338x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 Study enrolment and follow up
 * Discharge date was a random date applied to those not hospitalised
 ** Median length of stay of those hospitalised was added to those not hospitalised.

Figure 2 Study enrolment and follow up

338x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 Participant flow chart

Figure 3 Participant flow chart

338x190mm (300 x 300 DPI)

Supplementary Table 1

Association between number of hospital admissions and medication discontinuation at follow-up

	Antithrombotics (B01)		Lipid-lowering (C10)		Thyroid meds(H03)		Respiratory inhalers (R03)	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Hospitalised v non-hospitalised	1.05 (0.99,1.11), p=0.09	1.06 (0.98,1.12), p=0.49	1.06 (1.00,1.12), p=0.03	1.03 (0.97,1.10), p=0.26	0.84 (0.65,1.08), p=0.18	0.79 (0.59,1.06), p=0.11	0.84 (0.74,0.96), p=0.01	0.87 (0.76,0.99), p=0.03
Age (years)	1.02 (1.01,1.03), p<0.001	1.02 (1.02,1.04), p<0.001	1.04 (1.03,1.05), p<0.001	1.05 (1.04,1.06), p<0.001	1.03 (1.01,1.05), p=0.002	1.06 (1.04,1.08), p<0.001	1.02 (1.01,1.03), p=0.004	1.03 (1.02,1.05), p<0.001
<u>Gender:</u> Female v Male	1.02 (0.89,1.17), p=0.79	1.01 (0.87,1.16), p=0.90	0.85 (0.74,0.96), p=0.01	0.83 (0.72,0.95), p=0.01	0.84 (0.57,1.24), p=0.38	0.85 (0.56,1.30), p=0.46	1.04 (0.85,1.28), p=0.68	1.04 (0.84,1.28), p=0.74
<u>Insurance type:</u> Private v GMS/DVC patients	5.10 (4.31,6.04), p<0.001	5.38 (4.54,6.39), p<0.001	4.78 (4.06,5.62), p<0.001	5.69 (4.80,6.74), p<0.001	9.79 (6.90,13.89), p<0.001	11.69 (8.04,16.96), p<0.001	3.66 (2.78,4.82), p<0.001	3.79 (2.87,5.02), p<0.001
Number of repeat drug classes	0.99 (0.98,1.01), p=0.56	0.99 (0.97,1.01), p=0.25	1.01 (1.00,1.04), p=0.04	1.01 (0.99,1.03), p=0.28	0.98 (0.95,1.02), p=0.41	0.98 (0.93,1.03), p=0.44	0.97 (0.94,0.99), p=0.01	0.97 (0.94,0.99), p=0.02
<u>Charlson score</u> (>=1 v 0)	0.93 (0.80,1.07), p=0.31	0.93 (0.80,1.09), p=0.37	1.05 (0.91,1.21), p=0.48	0.97 (0.84,1.13), p=0.70	0.78 (0.56,1.08), p=0.15	0.79 (0.54,1.15), p=0.21	0.66 (0.53,0.81), p<0.001	0.71 (0.57,0.88), p=0.001
No of consultations in enrolment period	1.00 (0.99,1.01), p=0.62	1.00 (0.99,1.01), p=0.78	1.00 (0.99,1.01), p=0.69	1.00 (0.99,1.01), p=0.89	0.99 (0.97,1.00), p=0.11	1.00 (0.98,1.02), p=0.90	0.99 (0.98,1.00), p=0.02	1.00 (0.99,1.01), p=0.64

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	15-16
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	15
		(e) Describe any sensitivity analyses	16
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	See Figures
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	See Figures
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	See tables
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	16
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Unintended discontinuation of medication following hospitalisation: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024747.R1
Article Type:	Research
Date Submitted by the Author:	11-Oct-2018
Complete List of Authors:	Redmond, Patrick; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice; THIS Institute (The Healthcare Improvement Studies Institute), University of Cambridge McDowell, Ronald; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice Grimes, Tamasine C.; Trinity College Dublin, School of Pharmacy Boland, Fiona; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice McDonnell, Ronan; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice; Cancer Epidemiology and Health Services Group, Centre for Public Health, Queen's University Hughes, Carmel; Queens University Belfast, School of Pharmacy Fahey, Tom; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice
Primary Subject Heading:	Health services research
Secondary Subject Heading:	General practice / Family practice
Keywords:	transitions of care, medication reconciliation, continuity of patient care, cohort study

SCHOLARONE™
Manuscripts

1
2
3 **Unintended discontinuation of medication following hospitalisation: a**
4 **retrospective cohort study**
5

6
7 Patrick Redmond^{1,2}
8

9 Ronald McDowell^{2, 5}
10

11 Tamazine Grimes^{2,3}
12

13 Fiona Boland²
14

15 Ronan McDonnell²
16

17 Carmel Hughes^{2,4}
18

19 Tom Fahey²
20
21

22
23 ¹ THIS Institute (The Healthcare Improvement Studies Institute), University of
24 Cambridge, United Kingdom.

25
26 ²HRB Centre for Primary Care Research, RCSI medical school, Dublin 2, Ireland

27
28 ³School of Pharmacy, Trinity College Dublin, Dublin 2, Ireland

29
30 ⁴School of Pharmacy, Queen's University Belfast, Northern Ireland

31
32 ⁵Cancer Epidemiology and Health Services Research Group, Centre for Public Health,
33 Queen's University, Belfast
34
35

36 **Corresponding author:**
37

38 Dr Patrick Redmond
39

40 THIS Institute (The Healthcare Improvement Studies Institute)
41 University of Cambridge
42 Cambridge Biomedical Campus, Clifford Allbutt Building,
43 Cambridge CB2 0AH, United Kingdom
44
45

46 Email: patrick.redmond@thisinstitute.cam.ac.uk
47
48
49

50 **Abstract:** 333 words

51 **Main text:** 3,869 words
52
53
54

55 **Keywords:**
56
57
58
59
60

1
2
3 Transitions of care, medication reconciliation, continuity of patient care, cohort study
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objectives: Whether unintended discontinuation of common, evidence based, long-term medication occurs after hospitalisation; what factors are associated with unintended discontinuation; and whether the presence of documentation of medication at hospital discharge is associated with continuity of medication in general practice.

Design: Retrospective cohort study between 2012 and 2015.

Setting: Electronic records and hospital supplied discharge notifications in 44 Irish general practices

Participants: 20,488 patients aged 65 years or more prescribed long-term medication for chronic conditions.

Primary and secondary outcomes: Discontinuity of four evidence-based medication drug classes- antithrombotic, lipid-lowering, thyroid replacement drugs and respiratory inhalers in hospitalised versus non-hospitalised patients; patient and health system factors associated with discontinuity; impact of the presence of medication in the hospital discharge summary on continuity of medication in a patient's GP prescribing record at six months follow up.

Results: In patients admitted to hospital, medication discontinuity ranged from 6-11% in the six months post-hospitalisation. Discontinuity of medication is significantly lower for hospitalised patients taking respiratory inhalers (adjusted odds ratio (AOR) 0.63, 95% Confidence Interval (CI) (0.49, 0.80), $p < 0.001$) and thyroid medications (AOR 0.62, 95%CI (0.40, 0.96), $p = 0.03$). There is no association between discontinuity of medication and hospitalisation for antithrombotics (AOR 0.95, 95%CI (0.81, 1.11), $p = 0.49$) or lipid lowering medications (AOR 0.92, 95%CI (0.78, 1.08), $p = 0.29$). Older patients and those who paid to see their GP were more likely to experience increased odds of discontinuity in all four medicine groups. Less than half (39% to 47.4%) of patients had medication listed on their hospital discharge summary. Presence of medication on hospital discharge summary is significantly associated with continuity of medication in the GP prescribing record for lipid lowering medications (AOR 1.64,

1
2
3 95%CI (1.15, 2.36), $p=0.01$) and respiratory inhalers (AOR 2.97, 95%CI (1.68, 5.25),
4 $p<0.01$).
5
6

7 **Conclusion:** Discontinuity of evidence-based long-term medication is common.
8
9 Increasing age and private medical care are independently associated with a higher risk
10 of medication discontinuity. Hospitalisation is not associated with discontinuity but less
11 than half of hospitalised patients have medication recorded on their hospital discharge
12 summary.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Strengths and limitations of this study

1. This study includes prescribing data from a diverse group of general practices that includes non-fee and fee-paying patients.
2. We examined the impact of hospitalisation on continuity of evidence-based, long term medication after discharge using a novel data collection technique accessing GP prescribing records (as opposed to pharmacy dispensing records), codified chronic disease information and hospital provided discharge summary information.
3. We had no information on reasons for hospitalisation or therapeutic intent in terms of discontinuing medication.
4. We examined a limited number of medication groups and did not report on patient related-outcomes.

Introduction

Older patients are more likely to be prescribed multiple medications, have multiple chronic conditions, and experience increasing number of transitions of care.(1–3) Adherence to clinically appropriate, evidence-based therapies is important for lowering the risk of progression and complications related to their underlying chronic conditions.

Poor coordination of transitions of care is associated with adverse drug events (ADEs), rehospitalisation and discrepancies in medication lists.(4–9) Disruptions in medication continuity following hospitalisation have been reported.(10–13) In particular, omission of medication with known benefit has been noted in prescribing errors at discharge.(14–18) Previous studies have primarily examined large dispensing and/or administrative databases post hospitalisation to record the outcome of ‘discontinuity’.(10–13,19) Hospitalisation giving rise to discontinuity may be attributable to prescribing errors at discharge (e.g. omissions, communication issues), disruption in the prescribing process at the general practitioner (GP) level, failure or error in dispensing at the pharmacy level or the multitude of reasons for patient non-adherence. It is unclear where and why this discontinuity arises. There has been limited assessment of the immediate impact of hospitalisation on medication omission at hospital discharge which in turn, influences general practice repeat prescribing records.(20–24)

Aim and objectives

The aim of this study was to determine whether the potentially unintentional discontinuation of common, evidence-based medications for chronic diseases occurs after hospitalisation among older community dwelling adults. The medicine groups considered are: antithrombotics (antiplatelet or anticoagulants); lipid-lowering medications; thyroid medications; and respiratory inhalers. These medications are commonly prescribed in older populations, have a strong evidence base in terms of efficacy and once started are usually recommended to be continued on a long-term basis. Furthermore, the continuity of these medications in prescribing and dispensing

1
2
3 records has been the subject of study internationally – allowing for comparison of
4 results. (11,25–32).
5
6
7

8 We compare discontinuity of medication for each of the four medicine groups listed
9 above in the GP prescribing record over a six-month period between patients who had
10 been admitted to hospital and a group of patients who had not been admitted to
11 hospital. Second, we examine whether other patient and health-system factors are
12 associated with discontinuity of medication. A third objective is to assess whether
13 documentation of prescribing of the specific medication in the hospital discharge
14 summary record is associated with the presence of the same medication in the GP's
15 prescribing record in the following six months.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Study design

We conducted a retrospective cohort study, adhering to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.⁽³³⁾ Anonymous data were gathered using the general practice patient management system which includes prescribing, demographic and clinical records, and hospital supplied hospitalisation records. Project approval was received from the Irish Primary Care Research Network (IPCRN) and ethical approval was granted from the Irish College of General Practitioners.

Practice recruitment

A data extraction tool was developed with Socrates (providers of Electronic Health Record [EHR] software to a majority of GP practices in Ireland). Following piloting of the extraction tool, a convenience sample of practices using Socrates EHR and receiving electronic hospital discharge communication (n=48) were invited to participate. Forty-four GP practices (response rate 91%) provided consent to take part in the study. Thirty practices were in the catchment area of the Dublin hospitals, with one in the North-East of Ireland. Eleven practices were in the catchment area of the Galway hospitals and two in the catchment area of the Cork hospitals. Participating GPs were awarded continuing professional development points for their participation.

Medication classes

Four distinct patient cohorts were created based on the four medication classes: antithrombotics, lipid-lowering medications, thyroid medications, and respiratory inhalers (Figure 1 – Medication classes). These medications are commonly prescribed in older populations and once commenced, are usually continued on a long-term basis.

Study, enrolment and follow-up period criteria

The study period for each patient ranged from the 1st of January 2012 to the date when the data was extracted from the GP practice; this varied between practices, with the

1
2
3 median time being one year and 180 days (Figure 2 – Study enrolment and follow-up).
4 The study period included a one-year enrolment period, and a six-month follow-up
5 period. The enrolment period for each medication class was the earliest one-year period
6 post 1st January 2012 over which a patient was continuously prescribed medication from
7 that medication class. Continuously prescribed was defined as two prescriptions issued
8 at least five months apart. No hospitalisations were allowed during the enrolment period
9 to avoid misclassifying patients according to exposure. Patients could not be enrolled
10 before 65 years of age and could be enrolled into more than one of the medication
11 groups.
12
13
14
15
16
17
18
19

20 The start of the follow-up period, the period of time where discontinuity of medication
21 was estimated, was marked by an index date. For patients who had been hospitalised,
22 this was assigned as the day following discharge from hospital. For those individuals not
23 experiencing hospitalisation, the index date was randomly assigned following the
24 enrolment period. This method of generating a comparison group has been used
25 previously and is in line with assuming the medications are long-term and unlikely to be
26 discontinued.⁽¹¹⁾
27
28
29
30
31
32
33

34 The follow-up period comprised a six-month period following the index date. For
35 patients who were readmitted to hospital during this six-month period, the start of the
36 follow-up period was reset until after the next discharge until a six-month period free
37 from further hospitalisation was established. For all hospitalised patients the 180-day
38 follow-up period was extended to take account of their length of stay of the relevant
39 admission (reflecting the possibility that patients may have supplies of long-term
40 medication at home). A median length of stay for those hospitalised was added to the
41 unexposed group follow-up period.
42
43
44
45
46
47
48
49

50 Patients who were categorised as deceased/inactive at the extraction date or who had
51 no consultations after each follow-up period were excluded from the analyses. This
52 avoided misclassifying a patient who may, for example, have died in hospital or was
53
54
55
56
57
58
59
60

1
2
3 discharged to a long-term care facility and were not under the care of their previous
4 general practitioner.
5
6
7
8
9

10 *Explanatory variables of interest*

11
12 For the first two objectives, hospitalisation was the main explanatory variable of
13 interest. The electronic messaging system *Healthlink* provided discharge
14 messages in 41 practices to signal a hospitalisation (inpatient stay, not
15 Emergency Department attendances). Hospitalisation was coded manually by
16 research centre trained coders in four practices by examining the clinical
17 records directly (one practice provided both *Healthlink* electronic discharge
18 information and manually-coded discharge information). For the third objective,
19 the main exposure variable was presence of medication in the hospital
20 discharge summary note. This analysis was limited to hospitalised patients only.
21 For all analyses, we examined whether patient and health-system variables
22 might be associated with absence (primary analysis) or presence (secondary
23 analysis) of medication in the GP prescribing - age, gender, public / private
24 status, number of GP consultations, polypharmacy or multi-morbidity. (34–39)
25 Medication burden was calculated using RxRisk (34–40). All covariates were
26 measured during the enrolment period.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 *Outcomes*

41
42 The primary outcome was discontinuity of medication (failure to renew medication) in
43 one of the four, pre-specified medication classes in the general practitioner record over
44 the follow-up period. Changes within ATC class were allowed (e.g. between different
45 brands of inhalers). For each medication class, discontinuity of medication was
46 compared between those who had been hospitalised and those who had not. We
47 calculated univariable associations across the four medication classes and adjusted for
48 important confounders and other explanatory variables of interest. The secondary
49 outcome was presence of relevant medication in the patient's general practice
50
51
52
53
54
55
56
57
58
59
60

1
2
3 prescribing record following discharge from hospital. Again, this was estimated for each
4 medication cohort.
5
6
7

8 *Sample size*

9

10 The pilot phase and previous international studies in this area informed the calculation
11 (11,12). Sample size calculation was based on 90% power to detect a 3% difference in
12 the proportion of patients experiencing discontinuity. We assumed 11% of non-
13 hospitalised patients have medications unintentionally discontinued. Additionally, a 4:1
14 ratio of non-hospitalised to hospitalised patients (based on experience from the pilot
15 phase) with a statistical significance of 5% was used. This gave a total requirement of
16 8410 participants in any one medication cohort group.
17
18
19
20
21
22
23

24 *Plan of analysis*

25

26 The number of patients at each stage of the study is reported, including those
27 potentially eligible for enrolment, those enrolled into each of the four cohorts, and those
28 available for analysis in the follow-up period. Reasons for removal are documented at
29 each stage.
30
31
32
33

34 Descriptive statistics for the primary exposure (hospitalisation) and other explanatory
35 variables are reported. For all statistical analyses, multilevel modelling was used to
36 examine the association between each exposure and outcome of interest, adjusting for
37 patient and health-system variables. In these models, individual patient, are nested
38 within GP practices, giving rise to a (two level) multilevel model. Multilevel modelling
39 allows for the fact that patients within any given practice could reasonably be expected
40 to have more in common with each other than with those from a different practice- for
41 instance in terms of prescriber patterns.
42
43
44
45
46
47
48
49

50 For the primary outcome, a multilevel logistic multivariate model was fitted to estimate
51 the association between hospitalisation and discontinuity of medication for each
52 medication class in turn, adjusted for patient and health system variables- age, gender,
53 public/private status, Charlson score (comorbidity), number of repeat drug classes
54
55
56
57
58
59
60

1
2
3 (polypharmacy), and number of enrolment period GP consultations. Results are
4 reported as Adjusted Odds Ratios (AOR) with 95% Confidence Intervals (CI). These
5 analyses were repeated using the number of hospital admissions (count variable)
6 between the end of the enrolment period and the beginning of the follow-up period as
7 the main exposure, in order to assess the impact of repeated hospital admissions on
8 discontinuity of medication in the GP prescribing record.
9
10
11
12
13
14

15 For the secondary analyses, multilevel logistic multivariate regression was again used
16 to examine, for each medication group, the association between prescribing of the
17 specified medication at discharge from hospital and presence of the medication in the
18 subsequent GP prescribing history over the next six months. Models were adjusted for
19 the same patient and health-service variables listed above. Unadjusted analyses,
20 examining the association between each explanatory variable and outcome in turn are
21 reported for comparative purposes All analyses were performed using Stata V14.(41)
22
23
24
25
26
27
28

29 *Patient and Public Involvement*

30
31 Patients were not involved in the conception, design, or conduct of this research. We
32 plan to disseminate the findings to the public and patients through our contacts in
33 patient representative bodies, the popular media, and through the participating general
34 practices.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Cohort flow

A total of 92,048 patients had their records extracted from the 44 recruited practices, of which 53,921 (58.6%) were removed immediately due to insufficient data (patients with sociodemographic data only, or who had no prescriptions or consultations with the GP after 1 January 2012). (Figure 3 – Participant flow chart) A further 11,871 patients were removed due to not being prescribed any medications from the four drug groups of interest or having less than 12 months of follow-up data available to enable enrolment. The enrolment criteria were applied to the 26,256 remaining patients, creating four cohorts - antithrombotics (Anatomical Therapeutic Chemical (ATC) classification system, B01) (n=13,684), lipid-lowering medications (ATC C10) (n=14,427), thyroid medications (ATC H03) (n=3,484), and respiratory inhalers (ATC R03) (n=5,227). Out of the whole group of patients, 7,896 (38.5%) were enrolled in one medicine group, 9,184 (44.8%) in two groups, 3,074 (15.0%) in three groups and 334 (1.6%) in all four groups.

Descriptive statistics

The demographics of the participants within the four cohorts of those available at the follow-up period are presented in Table 1 (Participant Descriptives). Patients admitted to hospital tended to be slightly older, have more consultations with their general practitioner and higher levels of polypharmacy and co-morbidity during the enrolment period than patients who remained out of hospital.

Among patients who were not hospitalised, the percentage of participants experiencing discontinuation of medication at follow-up ranged from 8.5% (thyroid medications) to 17.0% (respiratory inhalers); and from 5.9% (thyroid medications) to 11.1% (respiratory inhalers) in those who were hospitalised. Levels of discontinuity were higher among those who had not been hospitalised in three of the four drug classes that were examined (Table 1).

Over two thirds of patients did not experience a hospital admission during follow up across the four medication groups (Table 2 – Hospital admissions). Of those admitted to

1
2
3 hospital, the percentage of patients experiencing a single admission ranged between
4 20.4% and 23.9% across the four medication groups. A minority of patients experienced
5 multiple medical admissions (Table 2).
6
7
8
9

10 *Univariable and multivariable associations*

11 There is no difference in terms of likelihood of discontinuity for lipid-lowering and
12 antithrombotic drugs between hospitalised and non-hospitalised patients.
13

14 Hospitalisation is associated with less odds of discontinuity of long term medication on
15 those prescribed thyroid medications and respiratory inhalers after adjustment for
16 important confounders (Table 3 – Analysis of Primary outcome). For all four medication
17 groups, older patients are more likely to experience discontinuity of medication than
18 younger patients, with the odds of discontinuity increasing by between 3%-6% per year
19 ($p < 0.001$). Private patients (those who paid for their own prescriptions and their GP
20 visits out of pocket) have the strongest association with discontinuity across all four
21 medicine groups with adjusted odds ratios (AOR) varying between 3.75, (95% CI 2.84,
22 4.96) for respiratory inhalers to 11.67, (95% CI 8.02, 16.96) for thyroid medications
23 (Table 3). Number of consultations, multi-morbidity, number of repeat medications and
24 gender are not associated with an increased odds of discontinuity.
25
26
27
28
29
30
31
32
33
34
35

36 *Repeated hospital admissions*

37 To assess the impact of repeated hospital admissions, models were re-estimated with
38 the hospital exposure defined as the number of hospital admissions (count) between the
39 end of the enrolment period and the beginning of the follow-up period. For
40 antithrombotics, lipid-lowering medications, and thyroid medications there was no
41 evidence of a statistically significant association between the number of admissions to
42 hospital and discontinuity of medication in the six-month follow up period. However, for
43 respiratory inhalers, the odds of discontinuity of medication fell by an estimated 13% per
44 additional admission to hospital after adjusting for confounders (AOR 0.87, (95%CI
45 0.76, 0.99), $p = 0.03$). For further details see Supplementary Table 1 (Repeated
46 admissions analysis).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Impact of medication specified in patient's hospital discharge summary*
4

5 Recording of medication on the hospital discharge summary was relatively poor, with
6 only 39.2% to 47.4% of patients having the relevant medication group documented
7 across the four medication groups. Medication recording had improved at six months
8 post discharge, being present in 89.2% to 94.7% of patient's GP clinical records across
9 medication groups (Table 4 – Documentation of medication at discharge and in the GP
10 record). Having medication listed on hospital discharge summary was independently
11 associated with medication being present on the GP record as six months follow up for
12 both lipid-lowering drugs and respiratory inhalers. Private patients were significantly less
13 likely to have the relevant medication in their GP prescribing record in the six-month
14 period following discharge from hospital than public patients. (Table 5 – Analysis of
15 secondary outcome).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Principal findings

Discontinuation of medication in patients who had been recently hospitalised ranged from 6 to 11% for commonly prescribed, evidence-based medicines, compared to 5-17% for non-hospitalised patients. Patients prescribed thyroid medications and respiratory inhalers, who experienced hospitalisation, actually had a lower risk of discontinuity. Public or private care played a significant role in the likelihood of medication being discontinued with the odds of discontinuation significantly higher for private patients than non-private patients in all medication groups. Increasing age is independently associated with an increased odds of discontinuation of medication. Lastly, recording of medication on hospital discharge summaries is incomplete, being present in less than 50% of discharged patients for all four medication groups. Presence of medication on hospital discharge summaries is associated with continuity on the GP prescribing record at six months for lipid lowering medication and respiratory inhalers.

Previous research

Findings from this observational study differs from similar studies in the US, both in the magnitude of discontinuation: reported to be between 12-19% for thyroid and antithrombotic medications; and in terms of the impact of hospitalisation, with hospitalisation being independently associated with discontinuation, when assessed using pharmacy dispensing data.(8,9,10,41) The impact of hospitalisation appears to be context and health system-specific, with some studies not finding a relationship between discontinuity and hospitalisation.(42–44). We found that increased number of medications was not associated with discontinuation; in the respiratory inhalers group patients were less likely to be discontinued if they had increased numbers of medications.(34,37–39,45–47) Like other studies we found that increasing age was independently associated with an increased discontinuity post discharge.(19)

This study reported a varying discontinuity rate across the four drug classes (lower in antithrombotics and higher in respiratory inhalers). This variation may be explained by

1
2
3 disease specific issues: altering doses of thyroxine replacement meaning repeat
4 prescriptions are not required; varying severity of disease – if a patient is asymptomatic
5 they are less likely to take the medication regularly; evolving diagnoses or clinical
6 considerations to patient beliefs about the effectiveness or benefits of the therapy or
7 their own susceptibility to illness.(48)
8
9
10
11
12

13 A particularly interesting finding in our study is the marked difference between publicly
14 funded and privately funded patients. Private patients were found to have a consistent
15 pattern of discontinuity independent of other patient and health system factors (Table 3).
16 Similarly, in hospitalised patients, being a private patient was associated with
17 discontinuity of medication recording in their GP record and significantly more likely at
18 six months follow up. There are possible explanations for this finding. Private patients
19 are not required to have their hospital discharge prescription transcribed by their GP
20 and may proceed directly to the pharmacy, thereby appearing as if their medication has
21 been discontinued by our method of outcome calculation. Nevertheless, lack of
22 continuity in the GP record raises concerns about completeness of the information a GP
23 in relation to a patient's medication file, monitoring requirements, potential drug-to-drug
24 interactions and other potential prescribing errors.
25
26
27
28
29
30
31
32
33
34
35

36 In keeping with findings from other studies, the quality of prescribing information
37 contained in hospital discharge summaries was incomplete for over half of discharged
38 patients, with the omission of essential medications common.(18,35) Furthermore lack
39 of medication reconciliation upon hospital discharge appeared to persist for at least six
40 months in general practice medication records.(21) The hospital discharge summary
41 used to determine discharge medication in this study is only one element of the
42 information normally provided to patients at discharge from hospital. A supplementary
43 discharge prescription may also be provided.(35) Therefore a discrepancy may arise
44 between the hospital discharge summary and additional discharge prescription, as
45 hospital doctors make judgements about what to include/exclude from discharge
46 prescriptions.(49) These parallel methods of providing post-discharge medication
47 information is a cause for concern and likely enhance risks of medication discontinuity.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 While lack of medication reconciliation following hospital discharge may be one possible
6 explanation for the reported discontinuity, there are other possible explanations, most
7 commonly poor patient adherence. A recent UK study of statin adherence reported
8 discontinuation rates of 27% at one year in those prescribed statins. Notably this was
9 examining primary non-adherence (failure to fill an initial prescription) as distinct from
10 what may be secondary non-adherence (inadequate medication possession over a
11 defined period of time) in this cohort).(50,51) The factors that influence adherence may
12 be patient, therapy, physician or health system related.(52) While this study was able to
13 control for some of these factors (demographics, comorbidities, public/private care
14 status) others were not recorded (socioeconomic status, side-effects, individual
15 physician behaviour and access to healthcare).

16
17 Lastly, inadequate adherence (and the related terms non-compliance and non-
18 concordance) may take many forms e.g. non-filling of prescriptions, altering doses,
19 stopping/starting. This study reported a varying discontinuity rate across the four drug
20 classes (lower in antithrombotics and higher in thyroid medications and respiratory
21 inhalers). This variation may be explained by disease-specific issues; for example,
22 altering doses of thyroxine replacement due to undulating severity of disease meaning
23 repeat prescriptions are not required; asymptomatic asthma patients not needing to take
24 bronchodilator inhalers;), evolving or clinical considerations such as the changing risk
25 benefit profile of an antithrombotic in a patient with a high risk of falls.(48)

40 41 *Strengths and limitations of study*

42
43 This is the largest Irish study to date to examine the effect of hospitalisation on the
44 continuity of evidence-based medication in the GP prescribing record. It is also the first
45 study to systematically use GP prescribing records (as opposed to pharmacy
46 dispensing records) and includes details of both private and public patients, unique
47 features of the mixed public/private health system in Ireland. The recruitment of GP
48 practices was not limited to one geographically area/hospital catchment and the
49 inclusion of multiple hospitals allowed comparison of messaging standards and their
50 impact on prescribing continuity, enhancing the generalisability of the findings.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 There are several limitations to this study. The medication groups were specifically
6 chosen to be evidence-based and long-term in their usage and the establishment of an
7 enrolment period of continuous usage over one year further ensures the pattern of
8 ongoing use. However, the primary outcome of discontinuation of medication was
9 applied to a prescribing database and does not contain information about indication or
10 therapeutic intent, for example intentional discontinuation of statins in end-of-life
11 patients. In addition, the nuances between different medications (e.g. warfarin and
12 aspirin) is lost by grouping in larger ATC classes.
13
14
15
16
17
18
19

20 The nature of data collection and the dataset itself also incur limitations. Hand written
21 prescriptions were not captured by this data collection technique. The follow-up of
22 participants from enrolment through to outcome calculation also required assumptions
23 to be made in preparing the data for analysis. However, the methods have been used
24 previously, and are in line with the underlying assumption that there should be no
25 difference between groups with both having 100% persistence of the medication in the
26 GP record. These findings reflect the Irish healthcare system and may not be applicable
27 in other systems with greater or lesser usage of electronic communication between
28 primary/secondary care or developed reconciliation systems. Lastly, the recording of
29 hospitalisation is likely to be variable within practices, with the *Healthlink* service
30 employed differently by hospitals with the possibility of misclassification of exposed
31 individuals. These methodological and data issues were explored in the sensitivity
32 analysis with no change in the overall findings.
33
34
35
36
37
38
39
40
41
42
43
44
45

46 *Clinical and healthcare policy implications*

47 Medication reconciliation, the process of creating the most accurate list of medications
48 at transition points, has been advocated by a number of different professional and
49 accrediting bodies internationally. Ensuring the accuracy of medication information at
50 transitions is reliant on good communication. The quality of electronic discharge
51 communication received by general practices and the possible association with
52
53
54
55
56
57
58
59
60

1
2
3 inappropriate discontinuation of evidence-based medication suggests more emphasis
4 needs to be placed on improving the quality of discharge communication. The HSE's
5 ePrescribing initiative and eScript pilot projects are efforts to improve the transfer of
6 medication information.(53,54)
7
8
9

10
11
12 Future efforts should focus on identifying high-risk individuals who are receiving
13 medications that would be the best targets for reconciliation studies and interventions.
14 Recent efforts have been made to develop a consensus about high risk medications
15 and methods of assessing the potential severity of medication omission.(55)
16
17
18
19

20 21 *Conclusions*

22
23 Discontinuity of evidence-based long-term medication is common. Increasing age and
24 private medical care are independently associated with a higher risk of medication
25 discontinuity. Hospitalisation was not associated with discontinuity but less than half of
26 hospitalised patients had medication recorded on their hospital discharge summary.
27 System based solutions that include ePrescribing are needed to enhance the transfer of
28 medication information across the primary/secondary care interface.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements:

We would like to thank Kevin O'Flannagan, Paul Dillon, Atieh Zarabzadeh, Khalid Munir, Oludare Alabi and Ronan McDonnell for their help in cleaning and categorising prescribing data. *Healthlink*, IPCRN and Socrates in design and data collection. We would also like to acknowledge the GP practices who participated in this study.

Funding:

This study was funded by the Health Research Board of Ireland, HRC-2014-1. This work was conducted as part of the HRB Scholar Programme in Health Services Research under Grant No. PHD/2007/16.

Ethics:

Ethical approval was granted from the Irish College of General Practitioners' Research Ethics Committee. GPs as individual practice data controllers gave informed consent to participate.

Conflict of interests:

We have read and understood BMJ policy on declaration of interests and declare that we have no competing interests.

Author Contributions:

PR initiated the project, designed data collection tools, monitored data collection, wrote the statistical analysis plan, cleaned and analysed the data, and drafted and revised the paper.

RMcDowell wrote the statistical analysis plan, cleaned and analysed the data and revised the paper.

TG designed the data collection tools, wrote the statistical analysis plan, and revised the paper.

FB designed the data collection tools, wrote the statistical analysis plan, and revised the paper.

RMcDonnell designed the data collection tools and revised the paper.

1
2
3 CH initiated the project, advised on the statistical analysis plan, and revised the paper.
4
5 TF initiated the project, monitored data collection, advised on the analysis plan and
6
7 revised the paper. He is guarantor.
8
9

10 Data statement

11 *Will individual participant data be available (including data dictionaries)?*
12
13

14
15 No additional data is available. A data sharing provision was not included in the
16
17 application to the research ethics committee for approval of this study.
18
19

20 *What data in particular will be shared?*
21

22 N/A
23

24 *What other documents will be available?*
25

26 N/A
27

28 *When will data be available (start and end dates)?*
29

30 N/A
31

32 *With whom?*
33

34 N/A
35

36 *For what types of analyses?*
37

38 N/A
39

40 *By what mechanism will data be made available?*
41

42 N/A
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012 Jul 7;380(9836):37–43.
2. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. *BMJ Open*. 2015 Sep 18;5(9):e008656.
3. Coleman EA, Smith JD, Raha D, Min SJ. Posthospital medication discrepancies: prevalence and contributing factors. *Arch Intern Med*. 2005 Sep 12;165(16):1842–7.
4. Moore C, Wisnivesky J, Williams S, McGinn T. Medical errors related to discontinuity of care from an inpatient to an outpatient setting. *J Gen Intern Med*. 2003 Aug;18:646–51.
5. van der Linden CMJ, Kerskes MCH, Bijl AMH, Maas HAAM, Egberts ACG, Jansen PAF. Represcription after adverse drug reaction in the elderly: a descriptive study. *Arch Intern Med*. 166(15):1666–7.
6. Coleman E. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. *J Am Geriatr Soc*. 2003 Apr;51(4):549–55.
7. Hammad EA, Wright DJ, Walton C, Nunney I, Bhattacharya D. Adherence to UK national guidance for discharge information: an audit in primary care. *Br J Clin Pharmacol*. 2014 Dec;78(6):1453–64.
8. Boockvar KS, Liu S, Goldstein N, Nebeker J, Siu A, Fried T. Prescribing discrepancies likely to cause adverse drug events after patient transfer. *Qual Saf Health Care*. 2009 Feb;18(1):32–6.
9. Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T. Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. *Arch Intern Med*. 2004 Mar 8;164(5):545–50.
10. Grimmsmann T, Schwabe U, Himmel W. The influence of hospitalisation on drug prescription in primary care—a large-scale follow-up study. *Eur J Clin Pharmacol*. 2007 Aug;63(8):783–90.
11. Bell CM, Brener SS, Gunraj N, Huo C, Bierman AS, Scales DC, et al. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. *JAMA*. 2011 Aug 24;306(8):840–7.
12. Stall NM, Fischer HD, Wu CF, Bierman AS, Brener S, Bronskill S, et al. Unintentional Discontinuation of Chronic Medications for Seniors in Nursing Homes: Evaluation of a National Medication Reconciliation Accreditation

- 1
2
3 Requirement Using a Population-Based Cohort Study. *Medicine (Baltimore)*. 2015
4 Jun;94(25):e899.
5
- 6 13. Bell CM, Bajcar J, Bierman AS, Li P, Mamdani MM, Urbach DR. Potentially
7 unintended discontinuation of long-term medication use after elective surgical
8 procedures. *Arch Intern Med*. 2006 Dec 11;166(22):2525–31.
9
- 10 14. Latimer SL, Chaboyer W, Hall T. Non-Therapeutic Medication Omissions:
11 Incidence and Predictors at an Australian Hospital. *J Pharm Pract Res*. 2011
12 Sep;41(3):188–91.
13
- 14 15. Perren A, Previsdomini M, Cerutti B, Soldini D, Donghi D, Marone C. Omitted and
15 unjustified medications in the discharge summary. *Qual Saf Health Care*. 2009
16 Jun;18(3):205–8.
17
- 18 16. Belda-Rustarazo S, Cantero-Hinojosa J, Salmeron-García a, González-García L,
19 Cabeza-Barrera J, Galvez J. Medication reconciliation at admission and
20 discharge: an analysis of prevalence and associated risk factors. *Int J Clin Pract*.
21 2015 Jul 22;1–7.
22
- 23 17. Elliott RA, Tran T, Taylor SE, Harvey PA, Belfrage MK, Jennings RJ, et al. Gaps
24 in continuity of medication management during the transition from hospital to
25 residential care: an observational study (MedGap Study). *Australas J Ageing*.
26 2012 Dec;31(4):247–54.
27
- 28 18. Wong JD, Bajcar JM, Wong GG, Alibhai SMH, Huh J-H, Cesta A, et al.
29 Medication reconciliation at hospital discharge: evaluating discrepancies. *Ann*
30 *Pharmacother*. 2008 Oct;42(10):1373–9.
31
- 32 19. Stuffken R, Heerdink ER, de Koning FHP, Souverein PC, Egberts ACG.
33 Association between hospitalization and discontinuity of medication therapy used
34 in the community setting in the Netherlands. *Ann Pharmacother*. 2008
35 Jul;42(7):933–9.
36
- 37 20. Cochrane RA, Mandal AR, Ledger-Scott M, Walker R. Changes in drug treatment
38 after discharge from hospital in geriatric patients. *BMJ*. 1992 Sep
39 19;305(6855):694–6.
40
- 41 21. O’Riordan C, Grimes T. Medication reconciliation on discharge to primary care
42 following an acute hospital admission. *Int J Clin Pharm*. 2014;36(4):836.
43
- 44 22. Mansur N, Weiss A, Hoffman A, Gruenewald T, Beloosesky Y. Continuity and
45 adherence to long-term drug treatment by geriatric patients after hospital
46 discharge: a prospective cohort study. *Drugs Aging*. 2008;25(10):861–70.
47
- 48 23. Viktil KK, Blix HS, Eek AK, Davies MN, Moger TA, Reikvam A. How are drug
49 regimen changes during hospitalisation handled after discharge: a cohort study.
50 *BMJ Open*. 2012 Nov 19;2(6):e001461–e001461.
51
- 52 24. Hammad E, Cadman B, Bale A, Holland R, Nunney I, Barton G, et al. Medication
53 errors: Do they persist in primary care and can they be identified? In: Royal
54 Pharmaceutical Society (RPS) Annual Conference. Birmingham, UK;
55
56
57

- 1
- 2
- 3 25. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence
- 4 of use of lipid-lowering medications: a cross-national study. *JAMA*. 1998 May
- 5 13;279(18):1458–62.
- 6
- 7 26. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term
- 8 persistence in use of statin therapy in elderly patients. *JAMA*. 288(4):455–61.
- 9
- 10 27. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of Drug
- 11 Adherence Rates Among Patients with Seven Different Medical Conditions.
- 12 *Pharmacotherapy*. 2008 Apr;28(4):437–43.
- 13
- 14 28. Ganz DA, Glynn RJ, Mogun H, Knight EL, Bohn RL, Avorn J. Adherence to
- 15 guidelines for oral anticoagulation after venous thrombosis and pulmonary
- 16 embolism. *J Gen Intern Med*. 2000 Nov;15(11):776–81.
- 17
- 18 29. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al.
- 19 Lessons from the Stroke Prevention in Atrial Fibrillation trials. *Ann Intern Med*.
- 20 2003 May 20;138(10):831–8.
- 21
- 22 30. Izquierdo JL, Paredero JM, Piedra R. Relevance of dosage in adherence to
- 23 treatment with long-acting anticholinergics in patients with COPD. *Int J Chron*
- 24 *Obstruct Pulmon Dis*. 2016;11:289–93.
- 25
- 26 31. National Clinical Guideline Centre(UK). Lipid Modification: Cardiovascular Risk
- 27 Assessment and the Modification of Blood Lipids for the Primary and Secondary
- 28 Prevention of Cardiovascular Disease. National Institute for Health and Clinical
- 29 Excellence: Guidance. 2014.
- 30
- 31 32. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, et al.
- 32 Canadian Thoracic Society recommendations for management of chronic
- 33 obstructive pulmonary disease. *Can Respir J*. 10 Suppl A:11A–65A.
- 34
- 35 33. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP,
- 36 et al. The Strengthening the Reporting of Observational Studies in Epidemiology
- 37 (STROBE) statement: guidelines for reporting observational studies. *Ann Intern*
- 38 *Med*. 2007 Oct 16;147(7624):806–8.
- 39
- 40 34. Hu SH, Capezuti E, Foust JB, Boltz MP, Kim H. Medication discrepancy and
- 41 potentially inappropriate medication in older Chinese-American home-care
- 42 patients after hospital discharge. *Am J Geriatr Pharmacother*. 2012
- 43 Oct;10(5):284–95.
- 44
- 45 35. Grimes TC, Duggan C, Delaney TP, Graham IM, Conlon KC, Deasy E, et al.
- 46 Medication details documented on hospital discharge: cross-sectional
- 47 observational study of factors associated with medication non-reconciliation. *Br J*
- 48 *Clin Pharmacol*. 2011 Mar;71(3):449–57.
- 49
- 50 36. Feldman LS, Costa LL, Feroli ER, Nelson T, Poe SS, Frick KD, et al. Nurse-
- 51 pharmacist collaboration on medication reconciliation prevents potential harm. *J*
- 52 *Hosp Med*. 2012 May;7(5):396–401.
- 53
- 54 37. Cornu P, Steurbaut S, Leysen T, De Baere E, Ligneel C, Mets T, et al.
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 Discrepancies in medication information for the primary care physician and the
4 geriatric patient at discharge. *Ann Pharmacother*. 2012 Jul;46(7–8):983–90.
5
- 6 38. Stitt DM, Elliott DP, Thompson SN. Medication discrepancies identified at time of
7 hospital discharge in a geriatric population. *Am J Geriatr Pharmacother*. 2011
8 Aug;9(4):234–40.
9
- 10 39. Hellström LM, Bondesson Å, Höglund P, Eriksson T. Errors in medication history
11 at hospital admission: prevalence and predicting factors. *BMC Clin Pharmacol*.
12 2012;12:9.
13
- 14 40. Sloan KL, Sales AE, Liu C-F, Fishman P, Nichol P, Suzuki NT, et al. Construction
15 and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix
16 instrument. *Med Care*. 2003 Jun;41(6):761–74.
17
- 18 41. StataCorp. Stata Statistical Software. College Station, TX;
19
- 20 42. Nelson LA, Graham M, Schaefer M. Characterization of Medication Discrepancies
21 Occurring at the Time of Discharge From an Adult State Psychiatric Inpatient
22 Facility. *Hosp Pharm*. 2011 Apr;46(4):254–61.
23
- 24 43. Cornish PL, Knowles SR, Marchesano R, Tam V, Shadowitz S, Juurlink DN, et al.
25 Unintended medication discrepancies at the time of hospital admission. *Arch*
26 *Intern Med*. 2005 Feb 28;165(4):424–9.
27
- 28 44. Climente-Martí M, García-Mañón ER, Artero-Mora A, Jiménez-Torres NV.
29 Potential risk of medication discrepancies and reconciliation errors at admission
30 and discharge from an inpatient medical service. *Ann Pharmacother*. 2010
31 Nov;44(11):1747–54.
32
- 33 45. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events
34 occurring following hospital discharge. *J Gen Intern Med*. 2005 Apr;20(4):317–23.
35
- 36 46. Grimes TC, Deasy E, Allen A, O'Byrne J, Delaney T, Barragry J, et al.
37 Collaborative pharmaceutical care in an Irish hospital: uncontrolled before-after
38 study. *BMJ Qual Saf*. 2014 Jul 6;23(7):574–83.
39
- 40 47. Dedhia P, Kravet S, Bulger J, Hinson T, Sridharan A, Kolodner K, et al. A quality
41 improvement intervention to facilitate the transition of older adults from three
42 hospitals back to their homes. *J Am Geriatr Soc*. 2009 Sep;57(9):1540–6.
43
- 44 48. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic
45 compliance: A review from the patient's perspective. *Ther Clin Risk Manag*. 2008
46 Feb;4(1):269–86.
47
- 48 49. Tully M, Cantrill J. What Hospital Doctors Think GPs Need In A Discharge
49 Summary. In: *WONCA Conference (London, UK)*. London; 2002.
50
- 51 50. Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and
52 restarting in patients on statin treatment: prospective open cohort study using a
53 primary care database. *BMJ*. 2016;353(i3305).
54
55
56
57
58
59

- 1
- 2
- 3 51. Raebel MA, Schmittiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing
- 4 Terminology and Definitions of Medication Adherence and Persistence in
- 5 Research Employing Electronic Databases. *Med Care*. 2013 Aug;51:S11–21.
- 6
- 7 52. Mauskop A, Borden WB. Predictors of statin adherence. *Curr Cardiol Rep*. 2011
- 8 Dec;13(6):553–8.
- 9
- 10 53. Health Service Executive (HSE). eHealth strategy for Ireland [Internet]. 2013
- 11 [cited 2016 Jun 7]. Available from: [http://www.ehealthireland.ie/Knowledge-](http://www.ehealthireland.ie/Knowledge-Information-Plan/eHealth-Strategy-for-Ireland.pdf)
- 12 [Information-Plan/eHealth-Strategy-for-Ireland.pdf](http://www.ehealthireland.ie/Knowledge-Information-Plan/eHealth-Strategy-for-Ireland.pdf)
- 13
- 14 54. Health Information & Quality Authority (HIQA). National Standard for Patient
- 15 Discharge Summary Information. 2013.
- 16
- 17 55. Doerper S, Godet J, Alexandra JF, Allenet B, Andres E, Bedouch P, et al.
- 18 Development and multi-centre evaluation of a method for assessing the severity
- 19 of potential harm of medication reconciliation errors at hospital admission in
- 20 elderly. *Eur J Intern Med*. 2015 Sep 21;26(7):491–7.
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Table 1

Descriptive statistics for participants in four evidence-based drug classes (ATC code)

Medication Group (No patients enrolled)	Antithrombotics (B01) (n=13,684)		Lipid-lowering (C10) (n=14,427)		Thyroid meds (H03) (n=3,484)		Respiratory inhalers (R03) (n=5,227)	
	Hospitalised (n=2,707)	Non-hospitalised (n=6,152)	Hospitalised (n=2,622)	Non-hospitalised (n=6,944)	Hospitalised (n=586)	Non-hospitalised (n=1,641)	Hospitalised (n=1,067)	Non-hospitalised (n=2,110)
	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)
Age (years)	78.38 (7.06)	75.32 (6.95)	77.05 (6.77)	73.78 (6.45)	78.34 (7.25)	74.59 (7.18)	76.88 (7.02)	74.29(6.90)
No of consultations in enrolment period	18.28 (10.40)	14.80 (9.66)	17.50 (10.09)	13.71 (8.79)	18.76 (10.29)	14.81 (9.10)	19.64 (11.09)	16.07 (10.57)
No of repeat drug classes during enrolment period	8.04 (3.72)	7.01 (3.45)	7.77 (3.75)	6.44 (3.41)	8.59 (4.30)	6.67 (3.87)	9.26 (4.24)	7.99 (4.13)
RxRisk during enrolment period	5.07 (2.05)	4.55 (1.89)	4.99 (2.09)	4.26 (1.97)	5.37 (2.42)	4.36 (2.09)	4.79 (2.18)	4.29 (2.12)
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Female	1,414 (52.23%)	3,176 (51.63%)	1,423 (54.27%)	3,957 (56.98%)	468 (79.86%)	1,349 (82.21%)	626 (58.67%)	1,276 (60.47%)
Insurance type: GMS/DVC	2,495 (92.17%)	5,495 (89.32%)	2,429 (92.64%)	6,194 (89.20%)	537 (91.64%)	1,445 (88.06%)	998 (93.53%)	1,898 (89.95%)
Charlson index of 1 or more	1,400 (51.72%)	2,638 (42.88%)	1,357 (51.75%)	2,736 (39.40%)	290 (49.49%)	543 (33.09%)	690 (64.67%)	1,120 (53.08%)
Patients experiencing one hospitalisation only during first follow-up period	2,011 (74.29%)	-	1,958 (74.68%)	-	457 (77.99%)	-	761 (71.32%)	-
No. (%) patients discontinued during 1 st follow-up period	288 (10.64%)	693 (11.26%)	282 (10.76%)	727 (10.47%)	35 (5.97%)	139 (8.47%)	118 (11.06%)	359 (17.01%)

ATC: Anatomical Therapeutic Chemical classification system

GMS: General Medical Services

DVC: Doctor Visit Card

SD: standard deviation

Table 2

Number of hospital admissions following enrolment for patients assessed for medication discontinuity at follow-up

Medication Group (No patients enrolled)	Antithrombotics (B01) (n=13,684)	Lipid-lowering (C10) (n=14,427)	Thyroid meds (H03) (n=3,484)	Respiratory inhalers (R03) (n=5,227)
No. patients at end of follow-up period				
0	6,152 (69.44%)	6,944 (72.59%)	1,641 (73.69%)	2,110 (66.41%)
1	2,011 (22.70%)	1,958 (20.45%)	457 (20.52%)	761 (23.95%)
2	448 (5.06%)	419 (4.38%)	90 (4.04%)	200 (6.30%)
3	140 (1.58%)	139 (1.45%)	26 (1.17%)	60 (1.89%)
4	25 (0.28%)	50 (5.23%)	5 (0.23%)	27 (0.85%)
5	8 (0.09%)	24 (0.25%)	6 (0.27%)	5 (0.16%)
6	7 (0.08%)	8 (0.09%)	1 (0.04%)	5 (0.16%)
>6	23 (0.26%)	24 (0.25%)	1 (0.04%)	14 (0.44%)

Table 3

Univariable and multivariable associations in four evidence-based drug classes (ATC code)

	Antithrombotics (B01)		Lipid-lowering (C10)		Thyroid meds(H03)		Respiratory inhalers (R03)	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Hospitalised v non-hospitalised	0.95 (0.82,1.10), p=0.49	0.95 (0.81,1.11), p=0.49	1.04 (0.89,1.20), p=0.64	0.92 (0.78,1.08), p=0.29	0.68 (0.46,1.00), p=0.05	0.62 (0.40,0.96), p=0.03	0.62 (0.49,0.78), p=0.001	0.63 (0.49,0.80), p<0.001
Age (years)	1.02 (1.01,1.03), p<0.001	1.03 (1.02,1.04), p<0.001	1.04 (1.03,1.05), p<0.001	1.05 (1.04,1.06), p<0.001	1.03 (1.01,1.05), p=0.002	1.06 (1.04,1.09), p<0.001	1.02 (1.01,1.03), p=0.004	1.04 (1.02,1.05), p<0.001
Gender: Female v Male	1.02 (0.89,1.17), p=0.79	1.00 (0.87,1.15), p=0.99	0.85 (0.74,0.96), p=0.01	0.82 (0.72,0.95), p=0.01	0.84 (0.57,1.24), p=0.38	0.85 (0.56,1.30), p=0.46	1.04 (0.85,1.28), p=0.68	1.03 (0.83,1.27), p=0.79
Insurance type: Private v GMS/DVC patients	5.10 (4.31,6.04), p<0.001	5.35 (4.50,6.34), p<0.001	4.78 (4.06,5.62), p<0.001	5.68 (4.48,6.73), p<0.001	9.79 (6.90,13.89), p<0.001	11.67 (8.02,16.96), p<0.001	3.66 (2.78,4.82), p<0.001	3.75 (2.84,4.96), p<0.001
Number of repeat drug classes	0.99 (0.98,1.01), p=0.56	0.99 (0.97,1.01), p=0.28	1.01 (1.00,1.04), p=0.04	1.01 (0.99,1.04), p=0.24	0.98 (0.95,1.02), p=0.41	0.98 (0.94,1.03), p=0.44	0.97 (0.94,0.99), p=0.01	0.97 (0.94,0.99), p=0.02
Charlson score (>=1 v0)	0.93 (0.80,1.07), p=0.31	0.94 (0.80,1.09), p=0.41	1.05 (0.91,1.21), p=0.48	0.98 (0.84,1.14), p=0.78	0.78 (0.56,1.08), p=0.15	0.80 (0.54,1.15), p=0.22	0.66 (0.53,0.81), p<0.001	0.71 (0.58,0.88), p=0.002
No of consultations in enrolment period	1.00 (0.99,1.01), p=0.62	1.00 (0.99,1.01), p=0.63	1.00 (0.99,1.01), p=0.69	1.00 (0.99,1.01), p=0.75	0.99 (0.97,1.00), p=0.11	1.00 (0.98,1.02), p=0.83	0.99 (0.98,1.00), p=0.02	1.00 (0.99,1.01), p=0.72

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

Table 4

Cross tabulation of patients by presence of medication on hospital discharge summary and in the GP prescribing record at six months following hospitalisation

Medication Group		GP Record Antithrombotics (B01) (n=1,991)†		GP record Lipid-lowering (C10) (n=1,954) †		GP record Thyroid meds(H03) (n=456) †		GP record Respiratory inhalers (R03) (n=757) †	
		Absent	Present	Absent	Present	Absent	Present	Absent	Present
Hospital discharge	Absent	113 (10.55%)	958 (89.45%)	123 (10.35%)	1,065 (89.65%)	16 (6.67%)	224 (93.33%)	65 (14.19%)	393 (85.81%)
Hospital discharge	Present	78 (8.48%)	842 (91.52%)	63 (8.22%)	703 (91.78%)	8 (3.70%)	208 (96.30%)	17 (5.69%)	282 (94.31%)

†patients with medication discontinued at hospital discharge excluded

Table 5

Multivariable association of required medication appearing in GP clinical record following discharge from hospital

	Antithrombotics (B01) (N=1,991)*		Lipid-lowering (C10) (N=1,954)*		Thyroid meds(H03) (N=456)*		Respiratory inhalers (R03) (N=757)*	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Medication listed on discharge summary	1.29 (0.95,1.76), p=0.11	1.34 (0.97,1.87), p=0.08	1.40 (0.99,1.97), p=0.06	1.64 (1.15,2.36), p=0.01	1.86 (0.77,4.43), p=0.16	1.76 (0.70,4.42), p=0.23	2.74 (1.57,4.78), p<0.001	2.97 (1.68,5.25), p<0.001
Age (years)	0.98 (0.96,1.00), p=0.03	0.98 (0.96,1.00), p=0.08	0.96 (0.94,0.98), p<0.001	0.95 (0.93,0.98), p<0.001	0.96 (0.91,1.02), p=0.16	0.96 (0.91,1.02), p=0.16	0.97 (0.94,1.01), p=0.12	0.96 (0.93,1.00), p=0.03
Female v Male	1.02 (0.76,1.38), p=0.90	0.97 (0.70,1.33), p=0.84	1.14 (0.84,1.56), p=0.39	1.15 (0.83,1.59), p=0.41	1.34 (0.52,3.49), p=0.54	1.35 (0.49,3.73), p=0.57	0.93 (0.58,1.50), p=0.77	0.87 (0.53,1.43), p=0.59
Insurance type: Private v GMS/DVC patients	0.18 (0.13,0.26), p<0.001	0.18 (0.12, 0.27), p<0.001	0.19 (0.12,0.28), p<0.001	0.17 (0.11,0.27), p<0.001	0.10 (0.04,0.26), p<0.001	0.10 (0.04,0.26), p<0.001	0.26 (0.14,0.50), p<0.001	0.26 (0.13,0.49), p<0.001
Number of repeat drug classes	1.04 (1.00,1.09), p=0.06	1.04 (0.99,1.09), p=0.11	0.99 (0.94,1.03), p=0.49	1.00 (0.96,1.06), p=0.86	1.06 (0.95,1.18), p=0.30	1.10 (0.96,1.26), p=0.18	1.07 (1.01,1.13), p=0.03	1.08 (1.00,1.15), p=0.06
Charlson score (>=1 v0)	1.14 (0.84,1.54), p=0.40	1.08 (0.79,1.49), p=0.63	0.76 (0.55,1.04), p=0.09	0.79 (0.56,1.11), p=0.18	1.06 (0.46,2.40), p=0.90	0.82 (0.33,2.03), p=0.67	0.98 (0.61,1.58), p=0.94	0.86 (0.52, 1.45), p=0.55
No of consultations in enrolment period	1.01 (0.99,1.03), p=0.19	1.00 (0.99,1.02), p=0.74	0.99 (0.97,1.01), p=0.22	0.99 (0.97,1.01), p=0.16	1.01 (0.97,1.06), p=0.63	0.99 (0.94, 1.04), p=0.63	1.02 (1.00,1.05), p=0.07	1.02 (0.98,1.04), p=0.41

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 – Medication classes

Figure 2 – Study enrolment and follow-up

Figure 3 – Participant flow chart

For peer review only

World Health Organization Anatomical Therapeutic Chemical (WHO - ATC) Classification System Code*	Drug class/name	Examples
C10	Lipid modifying agents	Statins, ezetimibe etc.
B01 (includes N02BA01)	Antithrombotics (antiplatelet or anticoagulant agents)	Aspirin, clopidogrel, warfarin, novel oral anticoagulants (NOACs) etc.
H03	Thyroid medication	Levothyroxine, carbimazole etc.
R03	Respiratory inhalers	Inhaled anticholinergics, short & long acting beta agonists, inhaled steroids

*ATC code groupings (as above) were used to ensure all component drugs within a class were included (e.g. prasugrel, ticagrelor etc.)
This chapter refers to each cohort by the first three figures of the ATC group.

Figure 1 Medication classes

Figure 1 Medication classes

338x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 Study enrolment and follow up
 * Discharge date was a random date applied to those not hospitalised
 ** Median length of stay of those hospitalised was added to those not hospitalised.

Figure 2 Study enrolment and follow up
 338x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 Participant flow chart

Figure 3 Participant flow chart

338x190mm (300 x 300 DPI)

Supplementary Table 1

Association between number of hospital admissions and medication discontinuation at follow-up

	Antithrombotics (B01)		Lipid-lowering (C10)		Thyroid meds(H03)		Respiratory inhalers (R03)	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Hospitalised v non-hospitalised	1.05 (0.99,1.11), p=0.09	1.06 (0.98,1.12), p=0.49	1.06 (1.00,1.12), p=0.03	1.03 (0.97,1.10), p=0.26	0.84 (0.65,1.08), p=0.18	0.79 (0.59,1.06), p=0.11	0.84 (0.74,0.96), p=0.01	0.87 (0.76,0.99), p=0.03
Age (years)	1.02 (1.01,1.03), p<0.001	1.02 (1.02,1.04), p<0.001	1.04 (1.03,1.05), p<0.001	1.05 (1.04,1.06), p<0.001	1.03 (1.01,1.05), p=0.002	1.06 (1.04,1.08), p<0.001	1.02 (1.01,1.03), p=0.004	1.03 (1.02,1.05), p<0.001
<u>Gender:</u> Female v Male	1.02 (0.89,1.17), p=0.79	1.01 (0.87,1.16), p=0.90	0.85 (0.74,0.96), p=0.01	0.83 (0.72,0.95), p=0.01	0.84 (0.57,1.24), p=0.38	0.85 (0.56,1.30), p=0.46	1.04 (0.85,1.28), p=0.68	1.04 (0.84,1.28), p=0.74
<u>Insurance type:</u> Private v GMS/DVC patients	5.10 (4.31,6.04), p<0.001	5.38 (4.54,6.39), p<0.001	4.78 (4.06,5.62), p<0.001	5.69 (4.80,6.74), p<0.001	9.79 (6.90,13.89), p<0.001	11.69 (8.04,16.96), p<0.001	3.66 (2.78,4.82), p<0.001	3.79 (2.87,5.02), p<0.001
Number of repeat drug classes	0.99 (0.98,1.01), p=0.56	0.99 (0.97,1.01), p=0.25	1.01 (1.00,1.04), p=0.04	1.01 (0.99,1.03), p=0.28	0.98 (0.95,1.02), p=0.41	0.98 (0.93,1.03), p=0.44	0.97 (0.94,0.99), p=0.01	0.97 (0.94,0.99), p=0.02
<u>Charlson score</u> (>=1 v 0)	0.93 (0.80,1.07), p=0.31	0.93 (0.80,1.09), p=0.37	1.05 (0.91,1.21), p=0.48	0.97 (0.84,1.13), p=0.70	0.78 (0.56,1.08), p=0.15	0.79 (0.54,1.15), p=0.21	0.66 (0.53,0.81), p<0.001	0.71 (0.57,0.88), p=0.001
No of consultations in enrolment period	1.00 (0.99,1.01), p=0.62	1.00 (0.99,1.01), p=0.78	1.00 (0.99,1.01), p=0.69	1.00 (0.99,1.01), p=0.89	0.99 (0.97,1.00), p=0.11	1.00 (0.98,1.02), p=0.90	0.99 (0.98,1.00), p=0.02	1.00 (0.99,1.01), p=0.64

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	15-16
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	15
		(e) Describe any sensitivity analyses	16
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	See Figures
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	See Figures
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	See tables
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	16
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Unintended discontinuation of medication following hospitalisation: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024747.R2
Article Type:	Research
Date Submitted by the Author:	01-Mar-2019
Complete List of Authors:	Redmond, Patrick; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice; THIS Institute (The Healthcare Improvement Studies Institute), University of Cambridge McDowell, Ronald; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice Grimes, Tamasine C.; Trinity College Dublin, School of Pharmacy Boland, Fiona; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice McDonnell, Ronan; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice; Cancer Epidemiology and Health Services Group, Centre for Public Health, Queen's University Hughes, Carmel; Queens University Belfast, School of Pharmacy Fahey, Tom; Royal College of Surgeons in Ireland, HRB Centre for Primary Care Research, Department of General Practice
Primary Subject Heading:	Health services research
Secondary Subject Heading:	General practice / Family practice
Keywords:	transitions of care, medication reconciliation, continuity of patient care, cohort study

SCHOLARONE™
Manuscripts

1
2
3 **Unintended discontinuation of medication following hospitalisation: a**
4 **retrospective cohort study**
5

6
7 Patrick Redmond^{1,2}
8

9 Ronald McDowell^{2, 5}
10

11 Tamazine Grimes^{2,3}
12

13 Fiona Boland²
14

15 Ronan McDonnell²
16

17 Carmel Hughes^{2,4}
18

19 Tom Fahey²
20
21

22
23 ¹ THIS Institute (The Healthcare Improvement Studies Institute), University of
24 Cambridge, United Kingdom.

25
26 ²HRB Centre for Primary Care Research, RCSI medical school, Dublin 2, Ireland

27
28 ³School of Pharmacy, Trinity College Dublin, Dublin 2, Ireland

29
30 ⁴School of Pharmacy, Queen's University Belfast, Northern Ireland

31
32 ⁵Cancer Epidemiology and Health Services Research Group, Centre for Public
33 Health, Queen's University, Belfast
34
35

36 **Corresponding author:**
37

38 Dr Patrick Redmond
39

40 THIS Institute (The Healthcare Improvement Studies Institute)
41 University of Cambridge
42 Cambridge Biomedical Campus, Clifford Allbutt Building,
43 Cambridge CB2 0AH, United Kingdom
44
45

46 Email: predmond@rcsi.ie
47
48
49

50 **Abstract:** 333 words

51 **Main text:** 3,869 words
52
53
54

55 **Keywords:**
56

57 Transitions of care, medication reconciliation, continuity of patient care, cohort study
58
59
60

Abstract

Objectives: Whether unintended discontinuation of common, evidence based, long-term medication occurs after hospitalisation; what factors are associated with unintended discontinuation; and whether the presence of documentation of medication at hospital discharge is associated with continuity of medication in general practice.

Design: Retrospective cohort study between 2012 and 2015.

Setting: Electronic records and hospital supplied discharge notifications in 44 Irish general practices

Participants: 20,488 patients aged 65 years or more prescribed long-term medication for chronic conditions.

Primary and secondary outcomes: Discontinuity of four evidence-based medication drug classes- antithrombotic, lipid-lowering, thyroid replacement drugs and respiratory inhalers in hospitalised versus non-hospitalised patients; patient and health system factors associated with discontinuity; impact of the presence of medication in the hospital discharge summary on continuity of medication in a patient's GP prescribing record at six months follow up.

Results: In patients admitted to hospital, medication discontinuity ranged from 6-11% in the six months post-hospitalisation. Discontinuity of medication is significantly lower for hospitalised patients taking respiratory inhalers (adjusted odds ratio (AOR) 0.63, 95% Confidence Interval (CI) (0.49, 0.80), $p < 0.001$) and thyroid medications (AOR 0.62, 95%CI (0.40, 0.96), $p = 0.03$). There is no association between discontinuity of medication and hospitalisation for antithrombotics (AOR 0.95, 95%CI (0.81, 1.11), $p = 0.49$) or lipid lowering medications (AOR 0.92, 95%CI (0.78, 1.08), $p = 0.29$). Older patients and those who paid to see their GP were more likely to experience increased odds of discontinuity in all four medicine groups. Less than half (39% to 47.4%) of patients had medication listed on their hospital discharge summary. Presence of medication on hospital discharge summary is significantly associated with continuity of medication in the GP prescribing record for lipid lowering medications (AOR 1.64, 95%CI (1.15, 2.36), $p = 0.01$) and respiratory inhalers (AOR 2.97, 95%CI (1.68, 5.25), $p < 0.01$).

1
2
3 **Conclusion:** Discontinuity of evidence-based long-term medication is common.
4 Increasing age and private medical care are independently associated with a higher
5 risk of medication discontinuity. Hospitalisation is not associated with discontinuity
6 but less than half of hospitalised patients have medication recorded on their hospital
7 discharge summary.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

Strengths and limitations of this study

1. This study includes prescribing data from a diverse group of general practices that includes non-fee and fee-paying patients.
2. We examined the impact of hospitalisation on continuity of evidence-based, long term medication after discharge using a novel data collection technique accessing GP prescribing records (as opposed to pharmacy dispensing records), codified chronic disease information and hospital provided discharge summary information.
3. We had no information on reasons for hospitalisation or therapeutic intent in terms of discontinuing medication.
4. We examined a limited number of medication groups and did not report on patient related-outcomes.

Introduction

Older patients are more likely to be prescribed multiple medications, have multiple chronic conditions, and experience increasing number of transitions of care.(1–3) Adherence to clinically appropriate, evidence-based therapies is important for lowering the risk of progression and complications related to their underlying chronic conditions.

Poor coordination of transitions of care is associated with adverse drug events (ADEs), rehospitalisation and discrepancies in medication lists.(4–9) Disruptions in medication continuity following hospitalisation have been reported.(10–13) In particular, omission of medication with known benefit has been noted in prescribing errors at discharge.(14–18) Previous studies have primarily examined large dispensing and/or administrative databases post hospitalisation to record the outcome of 'discontinuity'.(10–13,19) Hospitalisation giving rise to discontinuity may be attributable to prescribing errors at discharge (e.g. omissions, communication issues), disruption in the prescribing process at the general practitioner (GP) level, failure or error in dispensing at the pharmacy level or the multitude of reasons for patient non-adherence. It is unclear where and why this discontinuity arises. There has been limited assessment of the immediate impact of hospitalisation on medication omission at hospital discharge which in turn, influences general practice repeat prescribing records.(20–24)

Aim and objectives

The aim of this study was to determine whether the potentially unintentional discontinuation of common, evidence-based medications for chronic diseases occurs after hospitalisation among older community dwelling adults. The medicine groups considered are: antithrombotics (antiplatelet or anticoagulants); lipid-lowering medications; thyroid medications; and respiratory inhalers. These medications are commonly prescribed in older populations, have a strong evidence base in terms of efficacy and once started are usually recommended to be continued on a long-term basis. Furthermore, the continuity of these medications in prescribing and dispensing

1
2
3 records has been the subject of study internationally – allowing for comparison of
4 results. (11,25–32).
5
6
7

8 We compare discontinuity of medication for each of the four medicine groups listed
9 above in the GP prescribing record over a six-month period between patients who
10 had been admitted to hospital and a group of patients who had not been admitted to
11 hospital. Second, we examine whether other patient and health-system factors are
12 associated with discontinuity of medication. A third objective is to assess whether
13 documentation of prescribing of the specific medication in the hospital discharge
14 summary record is associated with the presence of the same medication in the GP's
15 prescribing record in the following six months.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Study design

We conducted a retrospective cohort study, adhering to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.⁽³³⁾ Anonymous data were gathered using the general practice patient management system which includes prescribing, demographic and clinical records, and hospital supplied hospitalisation records. Project approval was received from the Irish Primary Care Research Network (IPCRN) and ethical approval was granted from the Irish College of General Practitioners.

Practice recruitment

A data extraction tool was developed with Socrates (providers of Electronic Health Record [EHR] software to a majority of GP practices in Ireland). Following piloting of the extraction tool, a convenience sample of practices using Socrates EHR and receiving electronic hospital discharge communication (n=48) were invited to participate. Forty-four GP practices (response rate 91%) provided consent to take part in the study. Thirty practices were in the catchment area of the Dublin hospitals, with one in the North-East of Ireland. Eleven practices were in the catchment area of the Galway hospitals and two in the catchment area of the Cork hospitals. Participating GPs were awarded continuing professional development points for their participation.

Medication classes

Four distinct patient cohorts were created based on the four medication classes: antithrombotics, lipid-lowering medications, thyroid medications, and respiratory inhalers (Figure 1 – Medication classes). These medications are commonly prescribed in older populations and once commenced, are usually continued on a long-term basis.

Study, enrolment and follow-up period criteria

The study period for each patient ranged from the 1st of January 2012 to the date when the data was extracted from the GP practice; this varied between practices, with the median time being one year and 180 days (Figure 2 – Study enrolment and

1
2
3 follow-up). The study period included a one-year enrolment period, and a six-month
4 follow-up period. The enrolment period for each medication class was the earliest
5 one-year period post 1st January 2012 over which a patient was continuously
6 prescribed medication from that medication class. Continuously prescribed was
7 defined as two prescriptions issued at least five months apart. No hospitalisations
8 were allowed during the enrolment period to avoid misclassifying patients according
9 to exposure. Patients could not be enrolled before 65 years of age and could be
10 enrolled into more than one of the medication groups.
11
12
13
14
15
16
17

18
19 The start of the follow-up period, the period of time where discontinuity of medication
20 was estimated, was marked by an index date. For patients who had been
21 hospitalised, this was assigned as the day following discharge from hospital. For
22 those individuals not experiencing hospitalisation, the index date was randomly
23 assigned following the enrolment period. This method of generating a comparison
24 group has been used previously and is in line with assuming the medications are
25 long-term and unlikely to be discontinued.⁽¹¹⁾
26
27
28
29
30
31

32
33 The follow-up period comprised a six-month period following the index date. For
34 patients who were readmitted to hospital during this six-month period, the start of the
35 follow-up period was reset until after the next discharge until a six-month period free
36 from further hospitalisation was established. For all hospitalised patients the 180-day
37 follow-up period was extended to take account of their length of stay of the relevant
38 admission (reflecting the possibility that patients may have supplies of long-term
39 medication at home). A median length of stay for those hospitalised was added to
40 the unexposed group follow-up period.
41
42
43
44
45
46
47

48 Patients who were categorised as deceased/inactive at the extraction date or who
49 had no consultations after each follow-up period were excluded from the analyses.
50 This avoided misclassifying a patient who may, for example, have died in hospital or
51 was discharged to a long-term care facility and were not under the care of their
52 previous general practitioner.
53
54
55
56
57
58
59
60

Explanatory variables of interest

For the first two objectives, hospitalisation was the main explanatory variable of interest. The electronic messaging system *Healthlink* provided discharge messages in 41 practices to signal a hospitalisation (inpatient stay, not Emergency Department attendances). Hospitalisation was coded manually by research centre trained coders in four practices by examining the clinical records directly (one practice provided both *Healthlink* electronic discharge information and manually-coded discharge information). For the third objective, the main exposure variable was presence of medication in the hospital discharge summary note. This analysis was limited to hospitalised patients only. For all analyses, we examined whether patient and health-system variables might be associated with absence (primary analysis) or presence (secondary analysis) of medication in the GP prescribing - age, gender, public / private status, number of GP consultations, polypharmacy or multi-morbidity. (34–39) Medication burden was calculated using RxRisk (34–40). All covariates were measured during the enrolment period.

Outcomes

The primary outcome was discontinuity of medication (failure to renew medication) in one of the four, pre-specified medication classes in the general practitioner record over the follow-up period. Changes within ATC class were allowed (e.g. between different brands of inhalers). For each medication class, discontinuity of medication was compared between those who had been hospitalised and those who had not. We calculated univariable associations across the four medication classes and adjusted for important confounders and other explanatory variables of interest. The secondary outcome was presence of relevant medication in the patient's general practice prescribing record following discharge from hospital. Again, this was estimated for each medication cohort.

Sample size

The pilot phase and previous international studies in this area informed the calculation (11,12). Sample size calculation was based on 90% power to detect a 3% difference in the proportion of patients experiencing discontinuity. We assumed 11%

1
2
3 of non-hospitalised patients have medications unintentionally discontinued.
4 Additionally, a 4:1 ratio of non-hospitalised to hospitalised patients (based on
5 experience from the pilot phase) with a statistical significance of 5% was used. This
6 gave a total requirement of 8410 participants in any one medication cohort group.
7
8
9

10 11 *Plan of analysis*

12 The number of patients at each stage of the study is reported, including those
13 potentially eligible for enrolment, those enrolled into each of the four cohorts, and
14 those available for analysis in the follow-up period. Reasons for removal are
15 documented at each stage.
16
17
18
19

20
21
22 Descriptive statistics for the primary exposure (hospitalisation) and other explanatory
23 variables are reported. For all statistical analyses, multilevel modelling was used to
24 examine the association between each exposure and outcome of interest, adjusting
25 for patient and health-system variables. In these models, individual patient, are
26 nested within GP practices, giving rise to a (two level) multilevel model. Multilevel
27 modelling allows for the fact that patients within any given practice could reasonably
28 be expected to have more in common with each other than with those from a
29 different practice- for instance in terms of prescriber patterns.
30
31
32
33
34
35
36

37 For the primary outcome, a multilevel logistic multivariate model was fitted to
38 estimate the association between hospitalisation and discontinuity of medication for
39 each medication class in turn, adjusted for patient and health system variables- age,
40 gender, public/private status, Charlson score (comorbidity), number of repeat drug
41 classes (polypharmacy), and number of enrolment period GP consultations. Results
42 are reported as Adjusted Odds Ratios (AOR) with 95% Confidence Intervals (CI).
43 These analyses were repeated using the number of hospital admissions (count
44 variable) between the end of the enrolment period and the beginning of the follow-up
45 period as the main exposure, in order to assess the impact of repeated hospital
46 admissions on discontinuity of medication in the GP prescribing record.
47
48
49
50
51
52
53
54
55

56 For the secondary analyses, multilevel logistic multivariate regression was again
57 used to examine, for each medication group, the association between prescribing of
58
59
60

1
2
3 the specified medication at discharge from hospital and presence of the medication
4 in the subsequent GP prescribing history over the next six months. Models were
5 adjusted for the same patient and health-service variables listed above. Unadjusted
6 analyses, examining the association between each explanatory variable and
7 outcome in turn are reported for comparative purposes All analyses were performed
8 using Stata V14.(41)
9
10
11
12
13
14

15 *Patient and Public Involvement*

16 Patients were not involved in the conception, design, or conduct of this research. We
17 plan to disseminate the findings to the public and patients through our contacts in
18 patient representative bodies, the popular media, and through the participating
19 general practices.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Cohort flow

A total of 92,048 patients had their records extracted from the 44 recruited practices, of which 53,921 (58.6%) were removed immediately due to insufficient data (patients with sociodemographic data only, or who had no prescriptions or consultations with the GP after 1 January 2012). (Figure 3 – Participant flow chart) A further 11,871 patients were removed due to not being prescribed any medications from the four drug groups of interest or having less than 12 months of follow-up data available to enable enrolment. The enrolment criteria were applied to the 26,256 remaining patients, creating four cohorts - antithrombotics (Anatomical Therapeutic Chemical (ATC) classification system, B01) (n=13,684), lipid-lowering medications (ATC C10) (n=14,427), thyroid medications (ATC H03) (n=3,484), and respiratory inhalers (ATC R03) (n=5,227). Out of the whole group of patients, 7,896 (38.5%) were enrolled in one medicine group, 9,184 (44.8%) in two groups, 3,074 (15.0%) in three groups and 334 (1.6%) in all four groups.

Descriptive statistics

The demographics of the participants within the four cohorts of those available at the follow-up period are presented in Table 1 (Participant Descriptives). Patients admitted to hospital tended to be slightly older, have more consultations with their general practitioner and higher levels of polypharmacy and co-morbidity during the enrolment period than patients who remained out of hospital.

Among patients who were not hospitalised, the percentage of participants experiencing discontinuation of medication at follow-up ranged from 8.5% (thyroid medications) to 17.0% (respiratory inhalers); and from 5.9% (thyroid medications) to 11.1% (respiratory inhalers) in those who were hospitalised. Levels of discontinuity were higher among those who had not been hospitalised in three of the four drug classes that were examined (Table 1).

Over two thirds of patients did not experience a hospital admission during follow up across the four medication groups (Table 2 – Hospital admissions). Of those admitted to hospital, the percentage of patients experiencing a single admission

1
2
3 ranged between 20.4% and 23.9% across the four medication groups. A minority of
4 patients experienced multiple medical admissions (Table 2).
5
6
7

8 *Univariable and multivariable associations*

9
10 There is no difference in terms of likelihood of discontinuity for lipid-lowering and
11 antithrombotic drugs between hospitalised and non-hospitalised patients.
12 Hospitalisation is associated with less odds of discontinuity of long term medication
13 on those prescribed thyroid medications and respiratory inhalers after adjustment for
14 important confounders (Table 3 – Analysis of Primary outcome). For all four
15 medication groups, older patients are more likely to experience discontinuity of
16 medication than younger patients, with the odds of discontinuity increasing by
17 between 3%-6% per year ($p < 0.001$). Private patients (those who paid for their own
18 prescriptions and their GP visits out of pocket) have the strongest association with
19 discontinuity across all four medicine groups with adjusted odds ratios (AOR) varying
20 between 3.75, (95% CI 2.84, 4.96) for respiratory inhalers to 11.67, (95% CI 8.02,
21 16.96) for thyroid medications (Table 3). Number of consultations, multi-morbidity,
22 number of repeat medications and gender are not associated with an increased odds
23 of discontinuity.
24
25
26
27
28
29
30
31
32
33

34 In a sub-group analysis of the antithrombotics (B01) category, we found that
35 antiplatelets were independently associated with increased discontinuation after
36 hospitalisation (adjusted odds ratio 1.30, 95 % CI 1.12, 1.52), whilst for warfarin and
37 New Oral Anticoagulants (NOACs), no association between hospitalisation and
38 discontinuation was observed (adjusted odds ratio 0.97, 95% CI 0.68, 1.39). For both
39 antiplatelets and NOACs older age and private patients were independently
40 associated with discontinuation (Supplementary Table 1).
41
42
43
44
45
46
47

48 *Repeated hospital admissions*

49 To assess the impact of repeated hospital admissions, models were re-estimated
50 with the hospital exposure defined as the number of hospital admissions (count)
51 between the end of the enrolment period and the beginning of the follow-up period.
52 For antithrombotics, lipid-lowering medications, and thyroid medications there was
53 no evidence of a statistically significant association between the number of
54 admissions to hospital and discontinuity of medication in the six-month follow up
55 period. However, for respiratory inhalers, the odds of discontinuity of medication fell
56
57
58
59
60

1
2
3 by an estimated 13% per additional admission to hospital after adjusting for
4 confounders (AOR 0.87, (95%CI 0.76, 0.99), p=0.03). For further details see
5 Supplementary Table 2 (Repeated admissions analysis).
6
7
8

9
10 *Impact of medication specified in patient's hospital discharge summary*

11 Recording of medication on the hospital discharge summary was relatively poor, with
12 only 39.2% to 47.4% of patients having the relevant medication group documented
13 across the four medication groups. Medication recording had improved at six months
14 post discharge, being present in 89.2% to 94.7% of patient's GP clinical records
15 across medication groups (Table 4 – Documentation of medication at discharge and
16 in the GP record). Having medication listed on hospital discharge summary was
17 independently associated with medication being present on the GP record as six
18 months follow up for both lipid-lowering drugs and respiratory inhalers. Private
19 patients were significantly less likely to have the relevant medication in their GP
20 prescribing record in the six-month period following discharge from hospital than
21 public patients. (Table 5 – Analysis of secondary outcome).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Principal findings

Discontinuation of medication in patients who had been recently hospitalised ranged from 6 to 11% for commonly prescribed, evidence-based medicines, compared to 5-17% for non-hospitalised patients. Patients prescribed thyroid medications and respiratory inhalers, who experienced hospitalisation, actually had a lower risk of discontinuity. Public or private care played a significant role in the likelihood of medication being discontinued with the odds of discontinuation significantly higher for private patients than non-private patients in all medication groups. Increasing age is independently associated with an increased odds of discontinuation of medication. Lastly, recording of medication on hospital discharge summaries is incomplete, being present in less than 50% of discharged patients for all four medication groups. Presence of medication on hospital discharge summaries is associated with continuity on the GP prescribing record at six months for lipid lowering medication and respiratory inhalers.

Previous research

Findings from this observational study differs from similar studies in the US, both in the magnitude of discontinuation: reported to be between 12-19% for thyroid and antithrombotic medications; and in terms of the impact of hospitalisation, with hospitalisation being independently associated with discontinuation, when assessed using pharmacy dispensing data.(8,9,10,41) The impact of hospitalisation appears to be context and health system-specific, with some studies not finding a relationship between discontinuity and hospitalisation.(42–44). We found that increased number of medications was not associated with discontinuation; in the respiratory inhalers group patients were less likely to be discontinued if they had increased numbers of medications.(34,37–39,45–47) Like other studies we found that increasing age was independently associated with an increased discontinuity post discharge.(19)

A particularly interesting finding in our study is the marked difference between publicly funded and privately funded patients. Private patients were found to have a

1
2
3 consistent pattern of discontinuity independent of other patient and health system
4 factors (Table 3). Similarly, in hospitalised patients, being a private patient was
5 associated with discontinuity of medication recording in their GP record and
6 significantly more likely at six months follow up. There are possible explanations for
7 this finding. Private patients are not required to have their hospital discharge
8 prescription transcribed by their GP and may proceed directly to the pharmacy,
9 thereby appearing as if their medication has been discontinued by our method of
10 outcome calculation. Nevertheless, lack of continuity in the GP record raises
11 concerns about completeness of the information a GP in relation to a patient's
12 medication file, monitoring requirements, potential drug-to-drug interactions and
13 other potential prescribing errors.
14
15
16
17
18
19
20
21
22
23

24 In keeping with findings from other studies, the quality of prescribing information
25 contained in hospital discharge summaries was incomplete for over half of
26 discharged patients, with the omission of essential medications common.(18,35)
27 Furthermore lack of medication reconciliation upon hospital discharge appeared to
28 persist for at least six months in general practice medication records.(21) The
29 hospital discharge summary used to determine discharge medication in this study is
30 only one element of the information normally provided to patients at discharge from
31 hospital. A supplementary discharge prescription may also be provided.(35)
32 Therefore a discrepancy may arise between the hospital discharge summary and
33 additional discharge prescription, as hospital doctors make judgements about what
34 to include/exclude from discharge prescriptions.(48) These parallel methods of
35 providing post-discharge medication information is a cause for concern and likely
36 enhance risks of medication discontinuity.
37
38
39
40
41
42
43
44
45
46
47

48 While lack of medication reconciliation following hospital discharge may be one
49 possible explanation for the reported discontinuity, there are other possible
50 explanations, most commonly poor patient adherence. A recent UK study of statin
51 adherence reported discontinuation rates of 27% at one year in those prescribed
52 statins. Notably this was examining primary non-adherence (failure to fill an initial
53 prescription) as distinct from what may be secondary non-adherence (inadequate
54 medication possession over a defined period of time) in this cohort).(49,50) The
55 factors that influence adherence may be patient, therapy, physician or health system
56
57
58
59
60

1
2
3 related.(51) While this study was able to control for some of these factors
4 (demographics, comorbidities, public/private care status) others were not recorded
5 (socioeconomic status, side-effects, individual physician behaviour and access to
6 healthcare).
7
8
9

10
11 Lastly, inadequate adherence (and the related terms non-compliance and non-
12 concordance) may take many forms e.g. non-filling of prescriptions, altering doses,
13 stopping/starting. This study reported a varying discontinuity rate across the four
14 drug classes (lower in antithrombotics and higher in respiratory inhalers). The
15 variation between medication classes observed here may be explained by disease-
16 specific issues; for example, altering doses of thyroxine replacement due to
17 undulating severity of disease meaning repeat prescriptions are not required;
18 asymptomatic asthma patients not needing to take bronchodilator inhalers;), evolving
19 or clinical considerations such as the changing risk benefit profile of an
20 antithrombotic in a patient with a high risk of falls.(52)
21
22
23
24
25
26
27
28
29

30 *Strengths and limitations of study*

31
32
33 This is the largest Irish study to date to examine the effect of hospitalisation on the
34 continuity of evidence-based medication in the GP prescribing record. It is also the
35 first study to systematically use GP prescribing records (as opposed to pharmacy
36 dispensing records) and includes details of both private and public patients, unique
37 features of the mixed public/private health system in Ireland. The recruitment of GP
38 practices was not limited to one geographically area/hospital catchment and the
39 inclusion of multiple hospitals allowed comparison of messaging standards and their
40 impact on prescribing continuity, enhancing the generalisability of the findings.
41
42
43
44
45
46
47

48
49 There are several limitations to this study. The medication groups were specifically
50 chosen to be evidence-based and long-term in their usage and the establishment of
51 an enrolment period of continuous usage over one year further ensures the pattern
52 of ongoing use. However, the primary outcome of discontinuation of medication was
53 applied to a prescribing database and does not contain information about indication
54 or therapeutic intent, for example intentional discontinuation of statins in end-of-life
55 patients. In addition, the nuances between different medications (e.g. warfarin and
56
57
58
59
60

1
2
3 aspirin) is lost by grouping in larger ATC classes. Differential discontinuation within
4 the antithrombotic (B01) class of drugs was observed in a sub-group analysis, with
5 antiplatelet discontinuation associated with hospitalisation, whilst for NOACs
6 hospitalisation was not associated with discontinuation. These findings need to be
7 treated with caution, as they were not pre-specified and the magnitude of association
8 with antiplatelets is relatively modest.
9
10
11
12
13
14

15 The nature of data collection and the dataset itself also incur limitations. Hand written
16 prescriptions were not captured by this data collection technique. The follow-up of
17 participants from enrolment through to outcome calculation also required
18 assumptions to be made in preparing the data for analysis. However, the methods
19 have been used previously, and are in line with the underlying assumption that there
20 should be no difference between groups with both having 100% persistence of the
21 medication in the GP record. These findings reflect the Irish healthcare system and
22 may not be applicable in other systems with greater or lesser usage of electronic
23 communication between primary/secondary care or developed reconciliation
24 systems. Lastly, the recording of hospitalisation is likely to be variable within
25 practices, with the *Healthlink* service employed differently by hospitals with the
26 possibility of misclassification of exposed individuals. These methodological and data
27 issues were explored in the sensitivity analysis with no change in the overall findings.
28
29
30
31
32
33
34
35
36
37
38
39

40 *Clinical and healthcare policy implications*

41 Medication reconciliation, the process of creating the most accurate list of
42 medications at transition points, has been advocated by a number of different
43 professional and accrediting bodies internationally. Ensuring the accuracy of
44 medication information at transitions is reliant on good communication. The quality of
45 electronic discharge communication received by general practices and the possible
46 association with inappropriate discontinuation of evidence-based medication
47 suggests more emphasis needs to be placed on improving the quality of discharge
48 communication. The HSE's ePrescribing initiative and eScript pilot projects are
49 efforts to improve the transfer of medication information.(53,54)
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Future efforts should focus on identifying high-risk individuals who are receiving
4 medications that would be the best targets for reconciliation studies and
5 interventions. Recent efforts have been made to develop a consensus about high
6 risk medications and methods of assessing the potential severity of medication
7 omission.(55)
8
9
10
11
12
13

14 *Conclusions*

15
16 Discontinuity of evidence-based long-term medication is common. Increasing age
17 and private medical care are independently associated with a higher risk of
18 medication discontinuity. Hospitalisation was not associated with discontinuity but
19 less than half of hospitalised patients had medication recorded on their hospital
20 discharge summary. System based solutions that include ePrescribing are needed to
21 enhance the transfer of medication information across the primary/secondary care
22 interface.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements:

We would like to thank Kevin O'Flannagan, Paul Dillon, Atieh Zarabzadeh, Khalid Munir, Oludare Alabi and Ronan McDonnell for their help in cleaning and categorising prescribing data. *Healthlink*, IPCRN and Socrates in design and data collection. We would also like to acknowledge the GP practices who participated in this study.

Funding:

This study was funded by the Health Research Board of Ireland, HRC-2014-1. This work was conducted as part of the HRB Scholar Programme in Health Services Research under Grant No. PHD/2007/16.

Ethics:

Ethical approval was granted from the Irish College of General Practitioners' Research Ethics Committee. GPs as individual practice data controllers gave informed consent to participate.

Conflict of interests:

We have read and understood BMJ policy on declaration of interests and declare that we have no competing interests.

Author Contributions:

PR initiated the project, designed data collection tools, monitored data collection, wrote the statistical analysis plan, cleaned and analysed the data, and drafted and revised the paper.

RMcDowell wrote the statistical analysis plan, cleaned and analysed the data and revised the paper.

TG designed the data collection tools, wrote the statistical analysis plan, and revised the paper.

FB designed the data collection tools, wrote the statistical analysis plan, and revised the paper.

RMcDonnell designed the data collection tools and revised the paper.

CH initiated the project, advised on the statistical analysis plan, and revised the paper.

TF initiated the project, monitored data collection, advised on the analysis plan and revised the paper. He is guarantor.

Data statement

No additional data is available. A data sharing provision was not included in the application to the research ethics committee for approval of this study.

References

1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012 Jul 7;380(9836):37–43.
2. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. *BMJ Open*. 2015 Sep 18;5(9):e008656.
3. Coleman EA, Smith JD, Raha D, Min SJ. Posthospital medication discrepancies: prevalence and contributing factors. *Arch Intern Med*. 2005 Sep 12;165(16):1842–7.
4. Moore C, Wisnivesky J, Williams S, McGinn T. Medical errors related to discontinuity of care from an inpatient to an outpatient setting. *J Gen Intern Med*. 2003 Aug;18:646–51.
5. van der Linden CMJ, Kerskes MCH, Bijl AMH, Maas HAAM, Egberts ACG, Jansen PAF. Represcription after adverse drug reaction in the elderly: a descriptive study. *Arch Intern Med*. 166(15):1666–7.
6. Coleman E. Falling through the cracks: challenges and opportunities for improving transitional care for persons with continuous complex care needs. *J Am Geriatr Soc*. 2003 Apr;51(4):549–55.
7. Hammad EA, Wright DJ, Walton C, Nunney I, Bhattacharya D. Adherence to UK national guidance for discharge information: an audit in primary care. *Br J Clin Pharmacol*. 2014 Dec;78(6):1453–64.
8. Boockvar KS, Liu S, Goldstein N, Nebeker J, Siu A, Fried T. Prescribing discrepancies likely to cause adverse drug events after patient transfer. *Qual Saf Health Care*. 2009 Feb;18(1):32–6.
9. Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T. Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. *Arch Intern Med*. 2004 Mar 8;164(5):545–50.
10. Grimmsmann T, Schwabe U, Himmel W. The influence of hospitalisation on drug prescription in primary care--a large-scale follow-up study. *Eur J Clin Pharmacol*. 2007 Aug;63(8):783–90.

11. Bell CM, Brener SS, Gunraj N, Huo C, Bierman AS, Scales DC, et al. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. *JAMA*. 2011 Aug 24;306(8):840–7.
12. Stall NM, Fischer HD, Wu CF, Bierman AS, Brener S, Bronskill S, et al. Unintentional Discontinuation of Chronic Medications for Seniors in Nursing Homes: Evaluation of a National Medication Reconciliation Accreditation Requirement Using a Population-Based Cohort Study. *Medicine (Baltimore)*. 2015 Jun;94(25):e899.
13. Bell CM, Bajcar J, Bierman AS, Li P, Mamdani MM, Urbach DR. Potentially unintended discontinuation of long-term medication use after elective surgical procedures. *Arch Intern Med*. 2006 Dec 11;166(22):2525–31.
14. Latimer SL, Chaboyer W, Hall T. Non-Therapeutic Medication Omissions: Incidence and Predictors at an Australian Hospital. *J Pharm Pract Res*. 2011 Sep;41(3):188–91.
15. Perren A, Previsdomini M, Cerutti B, Soldini D, Donghi D, Marone C. Omitted and unjustified medications in the discharge summary. *Qual Saf Health Care*. 2009 Jun;18(3):205–8.
16. Belda-Rustarazo S, Cantero-Hinojosa J, Salmeron-García a, González-García L, Cabeza-Barrera J, Galvez J. Medication reconciliation at admission and discharge: an analysis of prevalence and associated risk factors. *Int J Clin Pract*. 2015 Jul 22;1–7.
17. Elliott RA, Tran T, Taylor SE, Harvey PA, Belfrage MK, Jennings RJ, et al. Gaps in continuity of medication management during the transition from hospital to residential care: an observational study (MedGap Study). *Australas J Ageing*. 2012 Dec;31(4):247–54.
18. Wong JD, Bajcar JM, Wong GG, Alibhai SMH, Huh J-H, Cesta A, et al. Medication reconciliation at hospital discharge: evaluating discrepancies. *Ann Pharmacother*. 2008 Oct;42(10):1373–9.
19. Stuffken R, Heerdink ER, de Koning FHP, Souverein PC, Egberts ACG. Association between hospitalization and discontinuity of medication therapy used in the community setting in the Netherlands. *Ann Pharmacother*. 2008 Jul;42(7):933–9.
20. Cochrane RA, Mandal AR, Ledger-Scott M, Walker R. Changes in drug treatment after discharge from hospital in geriatric patients. *BMJ*. 1992 Sep 19;305(6855):694–6.
21. O’Riordan C, Grimes T. Medication reconciliation on discharge to primary care following an acute hospital admission. *Int J Clin Pharm*. 2014;36(4):836.
22. Mansur N, Weiss A, Hoffman A, Gruenewald T, Beloosesky Y. Continuity and adherence to long-term drug treatment by geriatric patients after hospital discharge: a prospective cohort study. *Drugs Aging*. 2008;25(10):861–70.
23. Viktil KK, Blix HS, Eek AK, Davies MN, Moger TA, Reikvam A. How are drug regimen changes during hospitalisation handled after discharge: a cohort study. *BMJ Open*. 2012 Nov 19;2(6):e001461–e001461.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
24. Hammad E, Cadman B, Bale A, Holland R, Nunney I, Barton G, et al. Medication errors: Do they persist in primary care and can they be identified? In: Royal Pharmaceutical Society (RPS) Annual Conference. Birmingham, UK;
25. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. *JAMA*. 1998 May 13;279(18):1458–62.
26. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *JAMA*. 288(4):455–61.
27. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions. *Pharmacotherapy*. 2008 Apr;28(4):437–43.
28. Ganz DA, Glynn RJ, Mogun H, Knight EL, Bohn RL, Avorn J. Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism. *J Gen Intern Med*. 2000 Nov;15(11):776–81.
29. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. *Ann Intern Med*. 2003 May 20;138(10):831–8.
30. Izquierdo JL, Paredero JM, Piedra R. Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. *Int J Chron Obstruct Pulmon Dis*. 2016;11:289–93.
31. National Clinical Guideline Centre(UK). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Institute for Health and Clinical Excellence: Guidance. 2014.
32. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. *Can Respir J*. 10 Suppl A:11A–65A.
33. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007 Oct 16;147(7624):806–8.
34. Hu SH, Capezuti E, Foust JB, Boltz MP, Kim H. Medication discrepancy and potentially inappropriate medication in older Chinese-American home-care patients after hospital discharge. *Am J Geriatr Pharmacother*. 2012 Oct;10(5):284–95.
35. Grimes TC, Duggan C, Delaney TP, Graham IM, Conlon KC, Deasy E, et al. Medication details documented on hospital discharge: cross-sectional observational study of factors associated with medication non-reconciliation. *Br J Clin Pharmacol*. 2011 Mar;71(3):449–57.
36. Feldman LS, Costa LL, Feroli ER, Nelson T, Poe SS, Frick KD, et al. Nurse-pharmacist collaboration on medication reconciliation prevents potential harm. *J Hosp Med*. 2012 May;7(5):396–401.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
37. Cornu P, Steurbaut S, Leysen T, De Baere E, Ligneel C, Mets T, et al. Discrepancies in medication information for the primary care physician and the geriatric patient at discharge. *Ann Pharmacother*. 2012 Jul;46(7–8):983–90.
38. Stitt DM, Elliott DP, Thompson SN. Medication discrepancies identified at time of hospital discharge in a geriatric population. *Am J Geriatr Pharmacother*. 2011 Aug;9(4):234–40.
39. Hellström LM, Bondesson Å, Höglund P, Eriksson T. Errors in medication history at hospital admission: prevalence and predicting factors. *BMC Clin Pharmacol*. 2012;12:9.
40. Sloan KL, Sales AE, Liu C-F, Fishman P, Nichol P, Suzuki NT, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. *Med Care*. 2003 Jun;41(6):761–74.
41. StataCorp. Stata Statistical Software. College Station, TX;
42. Nelson LA, Graham M, Schaefer M. Characterization of Medication Discrepancies Occurring at the Time of Discharge From an Adult State Psychiatric Inpatient Facility. *Hosp Pharm*. 2011 Apr;46(4):254–61.
43. Cornish PL, Knowles SR, Marchesano R, Tam V, Shadowitz S, Juurlink DN, et al. Unintended medication discrepancies at the time of hospital admission. *Arch Intern Med*. 2005 Feb 28;165(4):424–9.
44. Climente-Martí M, García-Mañón ER, Artero-Mora A, Jiménez-Torres NV. Potential risk of medication discrepancies and reconciliation errors at admission and discharge from an inpatient medical service. *Ann Pharmacother*. 2010 Nov;44(11):1747–54.
45. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events occurring following hospital discharge. *J Gen Intern Med*. 2005 Apr;20(4):317–23.
46. Grimes TC, Deasy E, Allen A, O’Byrne J, Delaney T, Barragry J, et al. Collaborative pharmaceutical care in an Irish hospital: uncontrolled before-after study. *BMJ Qual Saf*. 2014 Jul 6;23(7):574–83.
47. Dedhia P, Kravet S, Bulger J, Hinson T, Sridharan A, Kolodner K, et al. A quality improvement intervention to facilitate the transition of older adults from three hospitals back to their homes. *J Am Geriatr Soc*. 2009 Sep;57(9):1540–6.
48. Tully M, Cantrill J. What Hospital Doctors Think GPs Need In A Discharge Summary. In: WONCA Conference (London, UK). London; 2002.
49. Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. *BMJ*. 2016;353(i3305).
50. Raebel MA, Schmittiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases. *Med Care*. 2013 Aug;51:S11–21.
51. Mauskop A, Borden WB. Predictors of statin adherence. *Curr Cardiol Rep*.

- 1
2
3 2011 Dec;13(6):553–8.
4
5 52. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic
6 compliance: A review from the patient’s perspective. *Ther Clin Risk Manag*.
7 2008 Feb;4(1):269–86.
8
9 53. Health Service Executive (HSE). eHealth strategy for Ireland [Internet]. 2013
10 [cited 2016 Jun 7]. Available from: [http://www.ehealthireland.ie/Knowledge-](http://www.ehealthireland.ie/Knowledge-Information-Plan/eHealth-Strategy-for-Ireland.pdf)
11 [Information-Plan/eHealth-Strategy-for-Ireland.pdf](http://www.ehealthireland.ie/Knowledge-Information-Plan/eHealth-Strategy-for-Ireland.pdf)
12
13 54. Health Information & Quality Authority (HIQA). National Standard for Patient
14 Discharge Summary Information. 2013.
15
16 55. Doerper S, Godet J, Alexandra JF, Allenet B, Andres E, Bedouch P, et al.
17 Development and multi-centre evaluation of a method for assessing the
18 severity of potential harm of medication reconciliation errors at hospital
19 admission in elderly. *Eur J Intern Med*. 2015 Sep 21;26(7):491–7.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1

Descriptive statistics for participants in four evidence-based drug classes (ATC code)

Medication Group (No patients enrolled)	Antithrombotics (B01) (n=13,684)		Lipid-lowering (C10) (n=14,427)		Thyroid meds (H03) (n=3,484)		Respiratory inhalers (R03) (n=5,227)	
	Hospitalised (n=2,707)	Non-hospitalised (n=6,152)	Hospitalised (n=2,622)	Non-hospitalised (n=6,944)	Hospitalised (n=586)	Non-hospitalised (n=1,641)	Hospitalised (n=1,067)	Non-hospitalised (n=2,110)
	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)	Mean(SD)
Age (years)	78.38 (7.06)	75.32 (6.95)	77.05 (6.77)	73.78 (6.45)	78.34 (7.25)	74.59 (7.18)	76.88 (7.02)	74.29(6.90)
No of consultations in enrolment period	18.28 (10.40)	14.80 (9.66)	17.50 (10.09)	13.71 (8.79)	18.76 (10.29)	14.81 (9.10)	19.64 (11.09)	16.07 (10.57)
No of repeat drug classes during enrolment period	8.04 (3.72)	7.01 (3.45)	7.77 (3.75)	6.44 (3.41)	8.59 (4.30)	6.67 (3.87)	9.26 (4.24)	7.99 (4.13)
RxRisk during enrolment period	5.07 (2.05)	4.55 (1.89)	4.99 (2.09)	4.26 (1.97)	5.37 (2.42)	4.36 (2.09)	4.79 (2.18)	4.29 (2.12)
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Female	1,414 (52.23%)	3,176 (51.63%)	1,423 (54.27%)	3,957 (56.98%)	468 (79.86%)	1,349 (82.21%)	626 (58.67%)	1,276 (60.47%)
Insurance type: GMS/DVC	2,495 (92.17%)	5,495 (89.32%)	2,429 (92.64%)	6,194 (89.20%)	537 (91.64%)	1,445 (88.06%)	998 (93.53%)	1,898 (89.95%)
Charlson index of 1 or more	1,400 (51.72%)	2,638 (42.88%)	1,357 (51.75%)	2,736 (39.40%)	290 (49.49%)	543 (33.09%)	690 (64.67%)	1,120 (53.08%)
Patients experiencing one hospitalisation only during first follow-up period	2,011 (74.29%)	-	1,958 (74.68%)	-	457 (77.99%)	-	761 (71.32%)	-
No. (%) patients discontinued during 1 st follow-up period	288 (10.64%)	693 (11.26%)	282 (10.76%)	727 (10.47%)	35 (5.97%)	139 (8.47%)	118 (11.06%)	359 (17.01%)

ATC: Anatomical Therapeutic Chemical classification system

GMS: General Medical Services

DVC: Doctor Visit Card

SD: standard deviation

Table 2

Number of hospital admissions following enrolment for patients assessed for medication discontinuity at follow-up

Medication Group (No patients enrolled)	Antithrombotics (B01) (n=13,684)	Lipid-lowering (C10) (n=14,427)	Thyroid meds (H03) (n=3,484)	Respiratory inhalers (R03) (n=5,227)
No. patients at end of follow-up period				
0	6,152 (69.44%)	6,944 (72.59%)	1,641 (73.69%)	2,110 (66.41%)
1	2,011 (22.70%)	1,958 (20.45%)	457 (20.52%)	761 (23.95%)
2	448 (5.06%)	419 (4.38%)	90 (4.04%)	200 (6.30%)
3	140 (1.58%)	139 (1.45%)	26 (1.17%)	60 (1.89%)
4	25 (0.28%)	50 (5.23%)	5 (0.23%)	27 (0.85%)
5	8 (0.09%)	24 (0.25%)	6 (0.27%)	5 (0.16%)
6	7 (0.08%)	8 (0.09%)	1 (0.04%)	5 (0.16%)
>6	23 (0.26%)	24 (0.25%)	1 (0.04%)	14 (0.44%)

Table 3

Univariable and multivariable associations in four evidence-based drug classes (ATC code)

	Antithrombotics (B01)		Lipid-lowering (C10)		Thyroid meds(H03)		Respiratory inhalers (R03)	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Hospitalised v non-hospitalised	0.95 (0.82,1.10), p=0.49	0.95 (0.81,1.11), p=0.49	1.04 (0.89,1.20), p=0.64	0.92 (0.78,1.08), p=0.29	0.68 (0.46,1.00), p=0.05	0.62 (0.40,0.96), p=0.03	0.62 (0.49,0.78), p=0.001	0.63 (0.49,0.80), p<0.001
Age (years)	1.02 (1.01,1.03), p<0.001	1.03 (1.02,1.04), p<0.001	1.04 (1.03,1.05), p<0.001	1.05 (1.04,1.06), p<0.001	1.03 (1.01,1.05), p=0.002	1.06 (1.04,1.09), p<0.001	1.02 (1.01,1.03), p=0.004	1.04 (1.02,1.05), p<0.001
Gender: Female v Male	1.02 (0.89,1.17), p=0.79	1.00 (0.87,1.15), p=0.99	0.85 (0.74,0.96), p=0.01	0.82 (0.72,0.95), p=0.01	0.84 (0.57,1.24), p=0.38	0.85 (0.56,1.30), p=0.46	1.04 (0.85,1.28), p=0.68	1.03 (0.83,1.27), p=0.79
Insurance type: Private v GMS/DVC patients	5.10 (4.31,6.04), p<0.001	5.35 (4.50,6.34), p<0.001	4.78 (4.06,5.62), p<0.001	5.68 (4.48,6.73), p<0.001	9.79 (6.90,13.89), p<0.001	11.67 (8.02,16.96), p<0.001	3.66 (2.78,4.82), p<0.001	3.75 (2.84,4.96), p<0.001
Number of repeat drug classes	0.99 (0.98,1.01), p=0.56	0.99 (0.97,1.01), p=0.28	1.01 (1.00,1.04), p=0.04	1.01 (0.99,1.04), p=0.24	0.98 (0.95,1.02), p=0.41	0.98 (0.94,1.03), p=0.44	0.97 (0.94,0.99), p=0.01	0.97 (0.94,0.99), p=0.02
Charlson score (>=1 v0)	0.93 (0.80,1.07), p=0.31	0.94 (0.80,1.09), p=0.41	1.05 (0.91,1.21), p=0.48	0.98 (0.84,1.14), p=0.78	0.78 (0.56,1.08), p=0.15	0.80 (0.54,1.15), p=0.22	0.66 (0.53,0.81), p<0.001	0.71 (0.58,0.88), p=0.002
No of consultations in enrolment period	1.00 (0.99,1.01), p=0.62	1.00 (0.99,1.01), p=0.63	1.00 (0.99,1.01), p=0.69	1.00 (0.99,1.01), p=0.75	0.99 (0.97,1.00), p=0.11	1.00 (0.98,1.02), p=0.83	0.99 (0.98,1.00), p=0.02	1.00 (0.99,1.01), p=0.72

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

Table 4

Cross tabulation of patients by presence of medication on hospital discharge summary and in the GP prescribing record at six months following hospitalisation

Medication Group		GP Record Antithrombotics (B01) (n=1,991)†		GP record Lipid-lowering (C10) (n=1,954) †		GP record Thyroid meds(H03) (n=456) †		GP record Respiratory inhalers (R03) (n=757) †	
		Absent	Present	Absent	Present	Absent	Present	Absent	Present
Hospital discharge	Absent	113 (10.55%)	958 (89.45%)	123 (10.35%)	1,065 (89.65%)	16 (6.67%)	224 (93.33%)	65 (14.19%)	393 (85.81%)
Hospital discharge	Present	78 (8.48%)	842 (91.52%)	63 (8.22%)	703 (91.78%)	8 (3.70%)	208 (96.30%)	17 (5.69%)	282 (94.31%)

†patients with medication discontinued at hospital discharge excluded

Table 5

Multivariable association of required medication appearing in GP clinical record following discharge from hospital

	Antithrombotics (B01) (N=1,991)*		Lipid-lowering (C10) (N=1,954)*		Thyroid meds(H03) (N=456)*		Respiratory inhalers (R03) (N=757)*	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Medication listed on discharge summary	1.29 (0.95,1.76), p=0.11	1.34 (0.97,1.87), p=0.08	1.40 (0.99,1.97), p=0.06	1.64 (1.15,2.36), p=0.01	1.86 (0.77,4.43), p=0.16	1.76 (0.70,4.42), p=0.23	2.74 (1.57,4.78), p<0.001	2.97 (1.68,5.25), p<0.001
Age (years)	0.98 (0.96,1.00), p=0.03	0.98 (0.96,1.00), p=0.08	0.96 (0.94,0.98), p<0.001	0.95 (0.93,0.98), p<0.001	0.96 (0.91,1.02), p=0.16	0.96 (0.91,1.02), p=0.16	0.97 (0.94,1.01), p=0.12	0.96 (0.93,1.00), p=0.03
Female v Male	1.02 (0.76,1.38), p=0.90	0.97 (0.70,1.33), p=0.84	1.14 (0.84,1.56), p=0.39	1.15 (0.83,1.59), p=0.41	1.34 (0.52,3.49), p=0.54	1.35 (0.49,3.73), p=0.57	0.93 (0.58,1.50), p=0.77	0.87 (0.53,1.43), p=0.59
Insurance type: Private v GMS/DVC patients	0.18 (0.13,0.26), p<0.001	0.18 (0.12, 0.27), p<0.001	0.19 (0.12,0.28), p<0.001	0.17 (0.11,0.27), p<0.001	0.10 (0.04,0.26), p<0.001	0.10 (0.04,0.26), p<0.001	0.26 (0.14,0.50), p<0.001	0.26 (0.13,0.49), p<0.001
Number of repeat drug classes	1.04 (1.00,1.09), p=0.06	1.04 (0.99,1.09), p=0.11	0.99 (0.94,1.03), p=0.49	1.00 (0.96,1.06), p=0.86	1.06 (0.95,1.18), p=0.30	1.10 (0.96,1.26), p=0.18	1.07 (1.01,1.13), p=0.03	1.08 (1.00,1.15), p=0.06
Charlson score (>=1 v0)	1.14 (0.84,1.54), p=0.40	1.08 (0.79,1.49), p=0.63	0.76 (0.55,1.04), p=0.09	0.79 (0.56,1.11), p=0.18	1.06 (0.46,2.40), p=0.90	0.82 (0.33,2.03), p=0.67	0.98 (0.61,1.58), p=0.94	0.86 (0.52, 1.45), p=0.55
No of consultations in enrolment period	1.01 (0.99,1.03), p=0.19	1.00 (0.99,1.02), p=0.74	0.99 (0.97,1.01), p=0.22	0.99 (0.97,1.01), p=0.16	1.01 (0.97,1.06), p=0.63	0.99 (0.94, 1.04), p=0.63	1.02 (1.00,1.05), p=0.07	1.02 (0.98,1.04), p=0.41

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

1
2
3 Figure 1 – Medication classes
4

5 Figure 2 – Study enrolment and follow-up
6

7 Figure 3 – Participant flow chart
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

World Health Organization Anatomical Therapeutic Chemical (WHO - ATC) Classification System Code*	Drug class/name	Examples
C10	Lipid modifying agents	Statins, ezetimibe etc.
B01 (includes N02BA01)	Antithrombotics (antiplatelet or anticoagulant agents)	Aspirin, clopidogrel, warfarin, novel oral anticoagulants (NOACs) etc.
H03	Thyroid medication	Levothyroxine, carbimazole etc.
R03	Respiratory inhalers	Inhaled anticholinergics, short & long acting beta agonists, inhaled steroids

*ATC code groupings (as above) were used to ensure all component drugs within a class were included (e.g. prasugrel, ticagrelor etc.)
This chapter refers to each cohort by the first three figures of the ATC group.

Figure 1 Medication classes

Figure 1 Medication classes

338x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 Study enrolment and follow up
 * Discharge date was a random date applied to those not hospitalised
 ** Median length of stay of those hospitalised was added to those not hospitalised.

Figure 2 Study enrolment and follow up
 338x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 Participant flow chart

Figure 3 Participant flow chart

338x190mm (300 x 300 DPI)

Supplementary Table 1

Subgroup analysis of B01 subgroups and primary outcome of discontinuity

	Unadjusted OR (95%CI, p-value)					Adjusted OR (95%CI, p-value)					
	Antithrombotics (B01) (n=13,684)	Aspirin and other antiplatelet agents: N02BA 01 B01AC (n=7613)	Warfarin: B01AA (n=1267)	NOACs: B01AE B01AF (n=235)	Warfarin + NOACs: B01AA B01AE B01AF (n=1475)	Antithrombotics (B01) (n=13,684)	Aspirin and other antiplatelet agents: N02BA 01 B01AC (n=7613)	Warfarin: B01AA (n=1267)	NOACs: B01AE B01AF (n=235)	Warfarin + NOACs: B01AA B01AE B01AF (n=1475)	
Hospitalised v non-hospitalised	0.95 (0.82,1.10), p=0.49	1.33 (1.15,1.53) p<0.001	1.11 (0.82,1.50) p=0.49	1.05 (0.47,2.35) p=0.90	1.09 (0.78,1.53) p=0.61	Hospitalised v non-hospitalised	0.95 (0.81,1.11), p=0.49	1.30 (1.12,1.52) p<0.001	0.95 (0.69,1.30) p=0.74	1.01 (0.43,2.34) p=0.99	0.97 (0.68,1.39) p=0.88
Age (years)	1.02 (1.01,1.03), p<0.001	1.03 (1.02,1.04) p<0.001	1.04 (1.01,1.06) p<0.001	1.00 (0.94,1.05) p=0.91	1.04 (1.01,1.06) p<0.001	Age (years)	1.03 (1.02,1.04), p<0.001	1.03 (1.02,1.04) p<0.001	1.05 (1.02,1.07) p<0.001	1.00 (0.94,1.06) p=0.96	1.04 (1.02,1.07) p<0.001
Gender: Female v Male	1.02 (0.89,1.17), p=0.79	0.94 (0.83,1.08) p=0.39	0.91 (0.68,1.23) p=0.55	1.10 (0.53,2.31) p=0.80	1.22 (0.88,1.69) p=0.23	Gender: Female v Male	1.00 (0.87,1.15), p=0.99	0.88 (0.76,1.01) p=0.07	0.81 (0.58,1.11) p=0.19	1.24 (0.56,2.73) p=0.59	1.18 (0.83,1.67) p=0.36
Private v Public (GMS/DVC) patients	5.10 (4.31,6.04), p<0.001	3.89 (3.28,4.63) p<0.001	3.87 (2.55,5.87) p<0.001	3.72 (1.44,9.58) p=0.01	4.05 (2.64,6.23) p<0.001	Private v Public (GMS/DVC) patients	5.35 (4.50,6.34), p<0.001	4.26 (3.57,5.08) p<0.001	4.33 (2.81,6.67) p<0.001	4.42 (1.62,12.02) p<0.001	4.38 (2.81,6.82) p<0.001
Number of repeat drug classes	0.99 (0.98,1.01), p=0.56	1.01 (0.99,1.03) p=0.26	1.01 (0.97,1.05) p=0.67	0.99 (0.90,1.10) p=0.87	0.98 (0.93,1.02) p=0.27	Number of repeat drug classes	0.99 (0.97,1.01), p=0.28	1.00 (0.98,1.02) p=0.86	1.01 (0.97,1.06) p=0.52	0.95 (0.85,1.07) p=0.38	0.97 (0.92,1.02) p=0.23
Charlson score (>=1 v0)	0.93 (0.80,1.07), p=0.31	0.84 (0.73,0.97) p=0.02	0.93 (0.69,1.26) p=0.65	0.96 (0.46,2.00) p=0.91	1.04 (0.74,1.46) p=0.81	Charlson score (>=1 v0)	0.94 (0.80,1.09), p=0.41	0.81 (0.70,0.95) p=0.01	0.84 (0.61,1.16) p=0.29	1.07 (0.50,2.31) p=0.87	1.00 (0.70,1.43) p=1.00
No of consultations in enrolment period	1.00 (0.99,1.01), p=0.62	1.01 (1.00,1.01) p=0.11	1.00 (0.99,1.02) p=0.52	1.02 (0.98,1.06) p=0.35	1.00 (0.98,1.01) p=0.68	No of consultations in enrolment period	1.00 (0.99,1.01), p=0.63	1.01 (1.00,1.01) p=0.23	1.00 (0.99,1.02) p=0.48	1.03 (0.99,1.07) p=0.15	1.00 (0.98,1.02) p=0.98

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

Supplementary Table 2

Association between number of hospital admissions and medication discontinuation at follow-up

	Antithrombotics (B01)		Lipid-lowering (C10)		Thyroid meds(H03)		Respiratory inhalers (R03)	
	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)	Unadjusted OR (95%CI, p-value)	Adjusted OR (95%CI, p-value)
Hospitalised v non-hospitalised	1.05 (0.99,1.11), p=0.09	1.06 (0.98,1.12), p=0.49	1.06 (1.00,1.12), p=0.03	1.03 (0.97,1.10), p=0.26	0.84 (0.65,1.08), p=0.18	0.79 (0.59,1.06), p=0.11	0.84 (0.74,0.96), p=0.01	0.87 (0.76,0.99), p=0.03
Age (years)	1.02 (1.01,1.03), p<0.001	1.02 (1.02,1.04), p<0.001	1.04 (1.03,1.05), p<0.001	1.05 (1.04,1.06), p<0.001	1.03 (1.01,1.05), p=0.002	1.06 (1.04,1.08), p<0.001	1.02 (1.01,1.03), p=0.004	1.03 (1.02,1.05), p<0.001
<u>Gender:</u> Female v Male	1.02 (0.89,1.17), p=0.79	1.01 (0.87,1.16), p=0.90	0.85 (0.74,0.96), p=0.01	0.83 (0.72,0.95), p=0.01	0.84 (0.57,1.24), p=0.38	0.85 (0.56,1.30), p=0.46	1.04 (0.85,1.28), p=0.68	1.04 (0.84,1.28), p=0.74
<u>Insurance type:</u> Private v GMS/DVC patients	5.10 (4.31,6.04), p<0.001	5.38 (4.54,6.39), p<0.001	4.78 (4.06,5.62), p<0.001	5.69 (4.80,6.74), p<0.001	9.79 (6.90,13.89), p<0.001	11.69 (8.04,16.96), p<0.001	3.66 (2.78,4.82), p<0.001	3.79 (2.87,5.02), p<0.001
Number of repeat drug classes	0.99 (0.98,1.01), p=0.56	0.99 (0.97,1.01), p=0.25	1.01 (1.00,1.04), p=0.04	1.01 (0.99,1.03), p=0.28	0.98 (0.95,1.02), p=0.41	0.98 (0.93,1.03), p=0.44	0.97 (0.94,0.99), p=0.01	0.97 (0.94,0.99), p=0.02
<u>Charlson score</u> (>=1 v0)	0.93 (0.80,1.07), p=0.31	0.93 (0.80,1.09), p=0.37	1.05 (0.91,1.21), p=0.48	0.97 (0.84,1.13), p=0.70	0.78 (0.56,1.08), p=0.15	0.79 (0.54,1.15), p=0.21	0.66 (0.53,0.81), p<0.001	0.71 (0.57,0.88), p=0.001
No of consultations in enrolment period	1.00 (0.99,1.01), p=0.62	1.00 (0.99,1.01), p=0.78	1.00 (0.99,1.01), p=0.69	1.00 (0.99,1.01), p=0.89	0.99 (0.97,1.00), p=0.11	1.00 (0.98,1.02), p=0.90	0.99 (0.98,1.00), p=0.02	1.00 (0.99,1.01), p=0.64

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	15-16
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	15
		(e) Describe any sensitivity analyses	16
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	See Figures
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	See Figures
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11
		(b) Report category boundaries when continuous variables were categorized	See tables
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	16
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	13-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.